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ABSTRACT
This thesis deals with neurochemica 1 investigations of 
the inhibitory synaptic transmitters 4-aminobutyric acid 
(GABA) and glycine. Much of the research concerns 
structure-activity correlations, and the very nature of 
these considerations has demanded that the techniques of 
organic chemistry, biochemistry and pharmacology be employed 
to achieve this purpose.
The nature of active conformations of GABA has been a 
problem of particular concern. Extended conformations of 
GABA appear to be important at the bicucul1ine-sensitive 
postsynaptic receptor, and in the initial binding to the 
active sites of GABA transaminase and the GABA transport 
system. All studies suggest that the inherent flexibility 
of this molecule is a property essential for biological 
activity .
Bicuculline antagonises the inhibitory action of GABA, 
and the bicuculline-GABA interaction was investigated to 
confirm that the interaction was postsynaptic, and to 
recognise structural elements necessary for the specific 
action of bicuculline.
4-Amino-3-hydroxyisoxazole, a conformationally 
restricted analogue of glycine and a possible metabolite 
of cycloserine, has been synthesised, but refinement of the 
synthesis is necessary before the biological properties of 
the molecule and a possible link to the central nervous 
system side effects of cycloserine can be investigated.
All mi eroe1ectrophoretic studies were done in
collaboration with Professor D.R. Curtis. All 
experiments in this thesis are my own work.
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I GENERAL INTRODUCTION
1Thudichum's classic, nA Treatise on the Chemical 
Constitution of the Brain" (1884), marks the beginning of 
formal neurochemical investigation, However, in an era of 
clinical neurology and Freudian psychiatry it was quickly 
forgotten, and neurochemistry lay dormant until the concept 
of the chemical transmission of nervous impulses initiated 
a desire to identify the chemical mediators involved. Thus 
the suggestion that nor- adrenaline acted as a specific 
chemical stimulant released from the endings of sympathetic 
nerve fibres (Elliott, 1904 § 1905), and the description of 
the "Vagusstoff", a substance which acted as a transmitter 
of vagus nerve impulses (Loewi, 1921) went unheeded, and it 
was not until the isolation and identification of 
acetylcholine (Dale and Dudley, 1929) that the investigation 
of the chemical nature of nervous activity began in earnest. 
Subsequent neurochemical research was devoted to a 
description of the chemical entities that could be extracted 
from the brain, and the study of their biological properties. 
From such investigations a number of possible transmitters 
in the nervous system have emerged (Table 1).
Implicit to an understanding of the nervous system is 
the "postulate" that an elicited response is largely a 
reflection of events in neural circuits (Sherrington, 1906; 
Roberts and Matthysse, 1970). An important corollary to 
this concept is that the identification of synaptic 
transmitters is of prime significance. Numerous criteria 
for transmitter identification have been suggested (Paton, 
1958; Curtis, 1961; Werman, 1966; Bradley, 1968; Curtis and 
Johnston, 1970) - those of Curtis and Johnston (1970) are
out lined below.
Table 1.
MAMMALIAN CENTRAL TRANSMITTERS
PROBABLE POSSIBLE
y -a m i n o b u t y r i c ACID Y-AMINO-3-HYDROXYBUTYRIC ACID
GLYCINE 3-ALANINE
GLUTAMIC ACID IMIDAZOLEACETIC ACID
ASPARTIC ACID TAURINE
ACETYLCHOLINE CYSTEIC ACID
NOR-ADRENALINE HISTAMINE
DOPAMINE ACETYLCARTINYLCHOLINE
5-HYDROXYTRYPTAMINE ATP / GTP 
CAMP / cGMP 
ERGOTHIONEINE
CYSTATHIONINE
2(1) The substance, and possibly the enzymes for its 
synthesis, should be present in or accumulated by the 
appropriate nerve endings.
(2) The substance should be released following impulses in 
the appropriate nerve fibres.
(3) The postsynaptic action of the substance should be 
identical with that of the natural transmitter.
(4) Compounds which block synaptic transmission by a 
specific postsynaptic effect must also antagonise the 
action of the suspected transmitter.
(5) The processes which inactivate or remove released 
transmitter should also terminate the action of the 
artificially administered substance.
The only approach to such a rigid set of requirements 
must be combined anatomical, chemical, pharmacological and 
physiological.
Ever increasing evidence suggests that neither 
acetylcholine, nor-adrenaline, 5-hydroxytryptamine nor 
dopamine are the transmitters of major excitatory and 
inhibitory pathways in the mammalian central nervous 
system. Although these and related substances may be 
important in subtle control mechanisms - the regulation 
of mood and behaviour and the fine control of voluntary 
movement - relatively simple amino acids (particularly 
4-aminobutyric acid, glycine, glutamate and aspartate) 
appear to function as the excitatory and inhibitory 
transmitters of the main central afferent and efferent
pathways .
3This thesis deals with neurochemical investigations of 
the inhibitory transmitters, 4 - aminobu t y r i c acid (GABA.) and 
glycine, and relates to all criteria, except (2), described 
ab ove .
II NEUROCHEMICAL INVESTIGATIONS
OF THE INHIBITORY AMINO ACID, 
y-AMINOBUTYRIC ACID.
41. GENERAL INTRODUCTION
Since the detection of GABA in extracts of nervous 
tissue (Awapara, Landau, Fuerst and Searle, 1950; Roberts and 
Frankel, 1950; Udenfriend, 1950) there has been increasing 
interest in the biological roles of this amino acid 
(Roberts and Kuriyama, 1968) . GABA, a component (Bazemore, 
Elliott and Florey, 1957) of Factor I (Elliott and Florey, 
1956) was suggested as a possible inhibitory transmitter in 
the central nervous system, because of its inhibitory effect 
on the crayfish stretch receptor.
Subsequently GABA was found to possess a depressant 
action on various parts of the central nervous system when 
administered topically, systemically or into the cerebrospinal 
fluid, and when administered electrophoretically to single 
neurones (reviewed by Curtis and Watkins, 1965). Despite 
initial findings that GABA appeared not to hyperpo1arise 
spinal motoneurones (Curtis, Phillis and Watkins, 1959) or 
cerebral cortical neurones (Krnjevic, 1964), such a 
hyperpolarisation was finally demonstrated on diverse neurones 
(Obata, 1965; Obata, Ito, Ochi and Sato, 1967; Krnjevic and 
Schwartz, 1967; Curtis, Hösli, Johnston and Johnston, 1968a; 
Bruggencate and Engberg, 1968).
Such a wealth of experimental findings naturally 
stimulated great interest in the molecular aspects of the 
biological actions produced by GABA, and pharmacological and 
neurochemical studies rapidly followed. Many GABA analogues 
were investigated, both by topical application (Purpura, 
Girado, Smith, Callan and Grundfest, 1959) and 
microelectrophoresis (Curtis and Watkins, 1960; Krnjevic and 
Phillis, 1963) in the hope that the molecular properties
5essential for the synaptic activity of GABA would be 
revealed. The resulting structure-activity correlations 
implicated both the intra-mo1 ecu 1ar distance between 
zwitterionic centres and the rotational freedom of the 
molecule as important factors governing the synaptic activity 
of GABA and related amino acids (Purpura, et al., 1959; 
reviewed by Curtis and Watkins, 1965). Curtis, et al.,
(1968a) and Curtis, Hbsli and Johnston (1968b) have classified 
amino acids tested upon spinal neurones as "glycine-like" and 
"GABA-like" on the basis of their blockade by strychnine.
Such a division follows from the finding that 
e lectrophoretically administered strychnine antagonises the 
inhibitory action of glycine and related amino acids, but not 
that of GABA and its analogues. The "GABA-like" amino acids 
included GABA, 4-amino-3-hydroxybutyric acid, 3-aminopropane 
sulphonic acid, 5-aminovaleric acid and 6-aminocaproic acid.
Such a "list" can be extended to include other "GABA-like" 
amino acids, muscimol and imidazoleacetic acid.
GABA antagonists
Recently the convulsant phthalideisoquinoline alkaloid, 
bicuculline (Fig. 1), when administered
microelectrophoretically or intravenously, has been shown to 
antagonise the inhibitory action of GABA, and to block certain 
central inhibitions (Curtis, Duggan, Felix and Johnston, 1970a). 
This selective antagonism strongly supported other evidence 
for GABA as an inhibitory transmitter at certain synapses in 
the mammalian central nervous system. Microelectrophoretic 
studies revealed bicucu11ine-sensitive synaptic inhibitions in 
the spinal cord (Curtis, Duggan, Felix and Johnston, 1971a),
BICUCULLINE
PICROTOXININ
PICROTIN
Fig. 1
Structures of bicuculline, picrotoxinin and picrotin.
6lateral vestibular nucleus (Curtis, Duggan, Felix, Johnston 
and McLennan, 1971b), ventrobasal thalamus (Duggan and 
McLennan, 1970), cerebellar cortex (Curtis and Felix, 1971; 
Bisti, Iosti and Strata, 1971), hippocampal cortex (Curtis, 
Felix and McLennan, 1970c), cerebral cortex (Curtis and 
Felix, 1971), olfactory bulb (Felix and McLennan, 1971; 
McLennan, 1971; Nicoll, 1971) and cuneate nucleus (Kelly and 
Renaud, 1971; Davidson and Reisine, 1971). Bicuculline also 
antagonises the inhibitory action of GABA in the brain stem 
(Tebecis, Hösli and Haas, 1971) and the superior cervical 
ganglion (de Groat, Lalley and Block, 1971). Furthermore, 
the bicuculline antagonism of the depressant action of GABA 
in the spinal cord supports the division of amino acids into 
"glycine-like" and "GABA-like" made on the basis of the 
antagonism by strychnine (Curtis, et al . , 1971a; Curt is. e t al. ,
1971b).
Picrotoxin, a potent convulsant isolated from the family 
Menispermaceae, appears to be an antagonist of GABA at some 
inhibitory synapses. Picrotoxin is a mixture of picrotoxinin 
and picrotin (Fig. 1) in a 1:1 molar ratio, with picrotoxinin 
being approximately 50 times more active than picrotin 
(Jarboe, Porter and Buckler, 1968). Picrotoxin antagonism of 
GABA is wide spread through invertebrates, and has been 
demonstrated at a variety of crustacean synapses (Elliott and 
Florey, 1956; Florey, 1957; Robbins and Van der Kloot, 1958) 
and at inhibitory neuromuscular synapses of the locust and 
grasshopper (Usherwood and Grundfest, 1965). An early 
analysis of the picrotoxin-GABA interaction at the lobster 
neuromuscular synapse suggested a competitive antagonism 
(Grundfest, Reuben and Rickies, 1959), but a later study
7(Takeuchi and Takeuchi, 1969) indicates this antagonism is of 
a non-competitive nature at the crayfish neuromuscular 
junction. These workers propose that two molecules of GABA 
combine with the receptor to increase the conductance of the 
junctional membrane, and that one molecule of picrotoxin 
binds at a specific site to depress the membrane conductance.
In contrast, the literature on the influence of 
picrotoxin on the mammalian central nervous system is 
remarkably confusing, as is well demonstrated by the widely 
conflicting reports that picrotoxin when administered 
e1 ectrophoretica 1ly has no effect on glycine or GABA on 
spinal interneurones (Curtis, et a 1 . , 1968b), blocks glycine 
on spinal interneurones (Davidoff and Aprison, 1969), 
slightly reduces the inhibitory effect of both glycine and 
GABA on a few spinal interneurones (Curtis, Duggan and 
Johnston, 1969), blocks GABA but not glycine on 15% of spinal 
interneurones tested (Engberg and Thaller, 1970) and blocks 
the action of GABA, but not that of glycine on neurones of 
the oculomotor nucleus (Obata and Highstein, 1970) and the 
olfactory bulb (Nicoll, 1971). A possible explanation for 
this lack of agreement about the mode of action of 
e1ectrophoretica 1ly administered picrotoxin is that the 
compound has no ionisable groups, and hence must be passed 
electrophoretica1ly by the uncertain route of electro-osmosis.
Picrotoxin administered intra-arterially blocks the 
depressant action of GABA, 4-amino-3-hydroxybutyric acid, 
3-aminopropane sulphonic acid and 3-alanine on the mammalian 
autonomic ganglia (De Groat, 1970). When administered 
intravenously (doses 1-2 mg/kg) picrotoxin reduces the 
prolonged inhibition of spinal reflexes (Eccies, Schmidt and
8Willis, 1963; Kellerth and Szumski, 1966) and the effect of 
e lectrophoretically applied GABA on presynaptic terminals in 
the cuneate nucleus (Galindo, 1969). Subconvu1sive doses 
apparently reduce inhibition in the olfactory bulb (Nicoll, 
1970), but doses of this order appear not to antagonise 
(Krnjevic, Randic and Straughan, 1966) or to only weakly 
antagonise transmission (Obata, et al ., 1967) at other
inhibitory synapses where GABA is the probable transmitter. 
Nevertheless, larger doses of intravenous picrotoxin do 
reduce inhibition of vestibular neurones following stimulation 
of the cerebellar flocculus (10 mg/kg; Ito, Highstein and 
Fukuda, 1970), of occulomotor neurones by vestibular impulses 
(4-10 mg/kg; Ito, Highstein and Tsuchiya, 1970) and by 
stimulation of the third cranial nerve (10-20 mg/kg;
Highstein, Ito and Ts' chiya, 1971), of Deiter’s nucleus 
following stimulation of the cerebellar anterior lobe (3-10 
mg/kg; Obata, Takeda, and Shinozaki, 1970) and of the 
substantia nigra by stimulation of the caudate nucleus (2.5 
mg/kg; Precht and Yoshida, 1971). This evidence, and 
comparison with the bicuculline antagonism of GABA, suggest 
that picrotoxin is a weaker GABA antagonist than bicuculline.
GABA synthesis
GABA appears to be synthesised by only one enzyme, 
L-glutamate-1-carboxylyase (glutamate decarboxylase,
E .C . 4.1 . 1 . 15), which catalyses the irreversible 
decarboxylation of glutamate to GABA (Baxter, 1970) . 
Putrescine has been intimated as a possible precursor of 
GABA (Seiler and Knogden, 1971; Seiler, Wiechmann, Fischer 
and Werner, 1971), but the evidence is far from convincing.
9GABA may also be synthesised from 4-hydroxybutyric acid (or 
the interconvertible y-butyrolactone) by a pathway not 
involving glutamic acid (Mitoma and Neubauer, 1968; Baxter, 
1970; Stransky, 1971). Glutamate decarboxylase (GAD) exists 
in at least two forms, designated GAD I and II (Kuriyama, 
Haber and Roberts, 1970; Haber, Kuriyama and Roberts, 1970): 
the brain enzyme GAD I being sensitive to anions and carbonyl 
reagents. Further evidence to support a transmitter role 
for GABA is the finding that nerve terminals of the molecular 
layer of the cerebellar cortex, which contain many inhibitory 
synapses, and have high GABA levels (Hirsch and Robins, 1962; 
Kuriyama, Haber, Sisken and Roberts, 1966; Otsuka, Obata, 
Miyata and Tanaka, 1971), are very rich in glutamate 
decarboxylase (Albers and Brady, 1959; Kuriyama, et al.,
1966) . Interestingly GABA may regulate its own level, for 
it has been reported to repress the activity of glutamate 
decarboxylase (Haber, Sze, Kuriyama and Roberts, 1970; Sze, 
1970; Sze and Lovell, 1970). Furthermore this regulatory 
role for GABA is supported by the observation that glutamate 
decarboxylase shows a negative cooper ativity with glutamate 
and should be less sensitive to changes in glutamate 
concentration (Turksy, 1971).
GABA Release
Release studies have demonstrated the specific release 
of GABA, but the nature of sample collection in such studies 
is necessarily remote and the origin of the released 
substance is often uncertain (Curtis and Johnston, 1970). 
GABA release has been demonstrated in vitro by stimulation
of brain slices, but there is uncertainty about the role of
10
calcium ions, which are considered to be important for 
transmitter release (Katz, Chase and Kopin, 1968), The 
spontaneous release of GABA from the cerebral cortex is 
dependent, on the state of activation of the brain (Jasper, 
Khan and Elliott, 1965), but the release of amino acids on 
stimulation of the reticular midbrain formation was shown 
to be relatively non-specific (Jasper and Koyama, 1969).
When the fourth ventricle of the cat was perfused the release 
of GABA into the perfusate could be measured, and despite 
variable spontaneous release, the release was markedly 
increased when the cerebellar cortex was stimulated (Obata 
and Takeda, 1969). Although the site of release was 
uncertain, it was very likely to be from the axon terminals 
of Purkinje cells in the cerebellar subcortical and 
vestibular nuclei. Recent studies using anaesthetised cats, 
injected with aminoxyacetic acid to reduce GABA metabolism 
by GABA transaminase, have demonstrated a specific calcium 
dependent release from the cortical surface during cortical 
"inhibition” . Although GABA was spontaneously released, 
there was an increased release during stimulation of the 
lateral geniculate body or the brain surface, but once again 
the origin of the released GABA is uncertain (Mitchell and 
Srinivasan, 1971; Iversen, Mitchell and Srinivasan, 1971).
GABA Inactivation
Once GABA has exerted its inhibitory effect at 
postsynaptic receptors its action must be terminated. Such 
termination of action might result enzymically, by receptor 
desensitisation, by simple diffusion or by active transport. 
Analysis of the brief time course of transmitter action
11
suggests that diffusion can account for the termination of 
transmitter action at some central synapses (Eccles and 
Jaeger, 1958). The mitochondrial enzyme GABA: 2-oxoglutarate 
aminotransferase (GABA transaminase, E .C .2.6.1 . 19), which 
catalyses the reversible transamination of GABA to succinic 
semialdehyde, is unlikely to be directly responsible for the 
enzymic inactivation of GABA (Curtis, Duggan and Johnston, 
1970b). GABA transaminase and succinic semialdehyde 
dehydrogenase form the GABA shunt (Roberts and Kuriyama, 1968), 
which may exert an important regulatory control on GABA levels 
in the central nervous system and thus indirectly influence 
the inactivation of GABA.
The GABA transport system demonstrated in cortical 
slices and homogenates (Iversen and Neal, 1968; Iversen and 
Johnston, 1971) is likely to be important in removing GABA 
from the synaptic cleft. A sodium-dependent binding of 
exogenous GABA to mouse brain homogenates at 0-4° has been 
reported and appears to involve slowly and rapidly 
equilibrating pools (Sano and Roberts, 1963; Varon, Weinstein, 
Kakefuda and Roberts, 1965; Weinstein, Varon, Muhleman and 
Roberts, 1965). Although its properties are similar to those 
of the GABA transport into slices and homogenates, it is 
difficult to rationalise the two processes as identical. The 
transport of GABA into cerebral slices is structurally specific, 
temperature sensitive, sodium dependent, active and shows 
saturation kinetics (Iversen and Neal, 1968). Furthermore 
there is regional variation of GABA uptake into slices of 
nervous tissue (Iversen and Johnston, 1971; Hbkfelt, Jonsson 
and Ljungdahl, 1970), and some correlation exists between the
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endogenous GABA levels and ^H-GABA accumulated (Hbkfelt, 
e t a l ., 1970). Electron microscopy autoradiographic studies
reveal that the accumulated ^H-GABA is localised in nerve 
terminals, and that approximately 30% of all terminals of
7.both cortical slices and homogenates contained H-GABA 
(Bloom and Iversen, 1971). GABA, a proposed transmitter in 
the feline spinal cord (Curtis, et a 1., 1971a), is 
accumulated by homogenates of spinal cord and appears to be 
localised in synaptosomes, providing further evidence for an 
inhibitory role (Iversen and Johnston, 1971). Such an uptake 
system would provide an efficient means of reconstituting 
presynaptic stores of GABA, and terminating its postsynaptic 
action .
Electron microscopy of excitatory and inhibitory 
presynaptic terminals suggests that excitatory and inhibitory 
synapses are characterised by "round" and "flattened" 
vesicles respectively (Uchizono, 1965; Bodian, 1966, 1967;
Gray, 1969). Vesicles of these shapes have been previously 
observed, but they were assigned no functional significance 
and regarded rather as fixation artifacts. Recently electron 
stereoscopy has shown that "flattened" vesicles can be 
further divided into "cylindrical" and "disc" shaped vesicles 
(Dennison, 1971). The existence of two distinct vesicle 
shapes at inhibitory synapses suggests there may be a 
relationship between the inhibitory transmitter involved, 
either GABA or glycine, and vesicle shape, which may thus be 
of diagnostic use (Matus and Dennison, 1971).
The evidence supporting an inhibitory role for GABA as a 
mammalian central transmitter is overwhelming, and satisfies 
the "criteria" suggested for transmitter identification. The
13
antagonism of inhibitory pathways by bicuculline indicates 
that GABA is a synaptic transmitter in the cerebral, 
hippocampal and cerebellar cortices, deeper nuclei and also 
in the spinal cord.
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2. ACETYLENIC ANALOGUES OF GABA
Recent studies strongly support a role for GABA as an 
inhibitory transmitter at certain synapses in the mammalian 
central nervous system. Although extensive structure-activity 
correlations implicate both the rotational freedom of the 
molecule and the intramolecular distance between the 
zwitterionic centres as important factors governing the 
synaptic activity of GABA and its analogues (Curtis and 
Watkins, 1965), little is known about the active 
conformation(s) of GABA.
The following observations provide pertinent information 
about the active conformation(s) of GABA recognised by the 
postsynaptic receptor. (1) Muscimol, an isoxazole isolated 
from Amanita muscaria, functions as a GABA analogue since its 
inhibitory action on central neurones is comparable with that 
of GABA both in potency (Johnston, Curtis, de Groat and 
Duggan, 1968), and with respect to antagonism by bicuculline 
(Curtis, et. al . , 1970a). Molecular orbital calculations 
suggest that GABA and muscimol can assume similar 
conformations as zwitterions with the charged centres (N+ and 
0 ) at least 5, and more likely, 6 Ä apart, (Kier and Truitt, 
1970). (2) The selective GABA antagonist bicuculline
exhibits some degree of structural similarity with particular 
conformations of GABA and muscimol (Curtis, et a. 1. , 1970a).
(3) X-ray crystallography indicates that GABA exists in a 
partially folded conformation in the solid state (Tomita,
1971; Steward, Player, Quilliam, Brown and Pringle, 1971).
(4) A model of the GABA receptor proposes that GABA adopts a 
folded conformation with a distance of less than 4.4 Ä 
between the charged centres (van Gelder, 1971).
15
Observations (1) and (2) suggest extended conformations for 
GABA, while (3) and (4) suggest extended folded 
conformations.
Since GABA is a flexible molecule and the energy 
barriers between its many conformers are likely to be quite 
small (Kier and Truitt, 1970), different conformations of 
GABA may interact with different receptors, Indeed, the 
establishment of a tight GABA-receptor complex might well 
stabilise an energetically unfavourable conformation of GABA, 
such that it becomes the active conformation of GABA at that 
receptor ,
To investigate GABA-receptor interactions, a study was 
undertaken of the effects of 4-aminotetrolic acid 
(4-aminobut-2-ynoic acid) and its N-substitu ted analogues on 
the postsynaptic receptor, the GABA metabolising enzymes,
GABA transaminase and glutamate decarboxylase, and the GABA 
transport system. These acetylenic amino acids are simple 
examples of conformationa1ly restricted GABA analogues, and 
may provide informat ion about the active conformation (s)
of GABA.
16
RESULTS
General
The tetrolic acid derivatives (Fig* 2) were synthesised 
by direct nucleophilic attack of the appropriate amine on 
4-ch1orotetro 1 ic acid (Olomucki, 1960) which was prepared via 
4-ch loro-but-2-yne-1-o1 (Bailey and Fujiwara, 1955) from 
the commercially available but-2-yne-1,4-diol (Fig. 3). All 
preparations were complicated by polysubstitution (as 
indicated by the development of a yellow or orange colouration 
by the reaction mixture with increasing reaction time), and 
higher yields obtained for the N-substituted tetrolic acids 
were probably due to the greater nucleophilicity of their 
amines relative to ammonia. Amination was particularly 
susceptible to polysubstitution, while pyrrolidine gave 
a decreased yield of the desired product with increased 
reaction time.
The acetylenic amino acids were found to be stable, 
crystalline, high melting zwitterionic compounds that were 
stronger acids than GABA. Their zwitterionic nature was 
particularly evident from the infrared spectra, which contained 
characteristic absorptions due to CO2“ at 1600-1650 and 
1325- 1360 cm“1, and N + H at 2000- 2300 cm 1 . Absorptions due to 
CsC were found at 2220-2250 cm’1.
The mass spectra of all the tetrolic acids displayed 
weak molecular ions. 4-Amino-, 4-piperidino- and 
4-pyrro1idinotetro1 i c acids all underwent fragmentation by a 
major breakdown pattern which involved initially the loss of 
a hydrogen radicle, followed by subsequent loss of carbon 
dioxide to yield the base peak of the spectra. Both 
4-piperazino- and 4-morpholinotetrolic acids, which have an
NH3CH2CH2CH2COO
n h 3c h 2c = c c o o
GABA
4-AMINOTETROLIC
ACID
/ ------\
o +n h c h 2c = c c o o
\___ /
4 -  M OR PHO LINO -  
TETROLIC ACID
/ ----- \
HN ♦NHCH2C=CCOO
\ ___ /
4-PIPERAZINO — 
TETROLIC ACID
N HCH ?C=CCOO
4 -  PIPERIDINO — 
TETROLIC ACID
♦NHCH,C=CCOO
4 —PYRROLIDINO — 
TETROLIC ACID
Fig. 2
Structures of GABA and acetylenic analogues
h o c h 2c =  c c h 2 o h
C IC H 2C =  CCOOH
Fig. 3
SOCI2
c i c h 2c =  c c h 2o h
R2NCH2C =  CCOOH
C r0 3
Synthetic scheme for the tetrolic acids
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additional heterocyclic atom, gave mass spectra in which 
most peaks were due to various modes of fragmentation of the 
heterocyclic ring.
When injected intravenously into adult mice,
4-aminotetro1ic acid had no apparent effect up to 240 mg/kg.
Microelectrophoresis
Each of the tetrolic acids inhibited the firing of 
central neurones - 4-aminotetrolic acid was the most potent 
of this series. Experiments with 4-aminotetro1ic acid were 
performed on spinal interneurones of 4 cats anaesthetised 
with pentobarbitone sodium. Extracellular action potentials 
were recorded by means of the centre barrel of seven barrel 
micropipettes and the compounds tested were administered 
e1ectrophoretica 1ly from the outer barrels of the micropipettes 
(Curtis, et al. , 1971a). The results obtained indicate that
4-aminotetro1ic acid had a clear GABA-like action in the 
spinal cord, where there is evidence that GABA functions as 
an inhibitory transmitter (Curtis, et al., 1971a).
4-Aminotetrolic acid was between one half and one fifth as 
active as GABA, based on the electrophoretic currents required 
to produce equal inhibitory effects. The inhibitory action of 
4-aminotetrolic acid, like that of GABA, could be reversibly 
antagonised by bicuculline (Fig. 4), whereas strychnine was 
ineffective as an antagonist.
GABA transaminase
Although the kinetic properties, substrate specificity 
and inhibition pat terns of brain GABA transaminase have been 
widely studied (Baxter, 1970), few simple convenient
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preparations of the enzyme or assay procedures have been 
described. Attempts to employ a crude brain homogenate, and 
to assay its GABA transaminase activity by the
spectrophotometric method of van Gelder (1968), were hindered 
by the extreme turbidity of the solutions. Furthermore, the 
estimation of GABA transaminase activity by the colorimetric 
determination of the glutamate formed in the reaction as the 
specific copper-glutamate chelate (Baxter and Roberts, 1958) 
was unsuitable because of the great difficulty in completely 
deproteinizing the incubation mixtures. The ethanol/water 
extraction procedure of Wallach (1961) was also found to be 
unsatisfactory because an active GABA transaminase preparation 
could not be isolated.
Active brain GABA transaminase homogenates have been 
successfully prepared in media containing pyridoxal phosphate 
(ca. 10% w/v), and as such retained their activity while 
frozen for many months (Pitts, Quick and Robins, 1965;
Sheridan, Sims and Pitts, 1967). Since GABA transaminase has 
a largely mitochondrial distribution (Salganicoff and 
de Robertis, 1963; Van Kempen, Van den Berg, Van der Helm and 
Veldstra, 1965), the brain GABA transaminase preparation 
always employed was a crude mitochondrial pellet taken up in 
10 volumes (with respect to the wet weight of rat cerebral 
grey matter) of 15 mM pyridoxal phosphate (containing 0.5 mM 
dithiothreitol) at pH 7.9. The preparation reached maximal 
activity after freezing and thawing several times, and 
maintained its activity while frozen for at least three months. 
This preparation was convenient and reproducible, and the 
GABA transaminase activity could be easily assayed by a 
radiochemical method based on that of Hall and Kravitz (1967),
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measuring the coupled formation of succinate from GABA, 
Furthermore, this assay could conveniently be modified to 
determine the activity of bacterial GABA transaminase, and 
hence possible inhibitors could be easily screened against 
both enzymes.
When tested at 1 mM, 4-aminotetro1ic acid, alone of the 
substituted tetrolic acids, significantly inhibited (32%) 
brain GABA transaminase activity. At this concentration 
4-aminotetrolie acid did not significantly influence bacterial 
transaminase activity, but at 5 mM it inhibited the activity 
of both the bacterial (61%) and the brain (81%) enzymes.
No evidence was obtained to indicate that 4-aminotetro1ic 
acid could replace GABA as an amino group donor for the 
production of glutamate by either transaminase. Furthermore, 
quantitative amino acid analyses indicated that 
4-aminotetro1ic acid, which was eluted just before aspartic 
acid in the two-buffer system of Spackman,Stein and Moore 
(1968), was not metabolised by the brain mitochondrial extract 
during 1 hour at 37° under the conditions employed in the 
transaminase assay in the absence of GABA. There were no 
significant differences in the levels of 4-aminotetro11c acid, 
glutamic acid or any of the other amino acids analysed in the 
reactions mixtures at zero time and after incubation for 30 
minutes and 1 hour.
Kinetic analysis of the inhibition of bacterial GABA 
transaminase by 4-aminotetro1ic acid indicated that this 
inhibition was of a linear non-competitive nature. This is 
illustrated by the Lineweaver-Burk plots of Fig, 5. Weighted 
averages of values for the inhibition constants from the 
computer analysis of two such experiments calculated by the
INHIBITION OF BACTERIAL
GABA AMINOTRANSFERASE
BY 4-AMINOTETROLIC ACID
GABA
Fig. 5
Analysis of data for the inhibition of bacterial 
GABA transaminase activity by 4-aminotetrolic acid (ATA). 
The points are experimental. The lines represent the 
computed fit to linear non-competitive inhibition. 
Velocities (v) are expressed as change in optical density 
at 340 my/rain/0.5 mg acetone powder.
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formulae given by Morrison and James (1965), were 
Kis = 1.36 ± 0.18 mM and Kli - 11.7 ± 4.6 mM,
Initial velocity studies of the reaction catalysed by 
this enzyme have been carried out by Scott and Jakoby (1959). 
While no product inhibition or isotope exchange experiments 
were done, their initial velocity measurements in the presence 
of varying substrate concentrations were consistent with a 
Pinj-pong mechanism, as might be expected for a transaminase 
enzyme (Cleland, 1963a). If this is so then the rate equation 
for non-competitive inhibition by 4-aminotetro lie acid (I) 
with respect to the variable substrate GABA (A) in the 
presence of a fixed concentration of the second substrate 
2- oxog 1 ut arat e (B) is
1 = Ka [ 1 + I ] + 1 IKb (l + ) + 1] (1)
V VA Kis V B
using the nomenclature of Cleland (1963a). In this equation 
K^s and are dissociation constants. The slope inhibition
constant measured experimentally was equal to the dissociation 
constant for the reaction of the inhibitor with the form of 
the enzyme with which the variable substrate combined, i.e. 
the pyridoxal form of the enzyme. The experimental intercept 
inhibition constant was however dependent on the 
concentration of the second substrate (B), and its Michaelis 
constant (K^), and was related to the dissociation constant 
in equation (1) by the following equation
experimental = K^(l + B_) (2)
Therefore, using the value of 1.67 mM for calculated from 
the data of Scott and Jakoby (1959), the dissociation constant
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for 4-aminotetro lie acid from the pyridoxamine form of the 
enzyme was calculated to be 7.3 mM,
In contrast to these results with the bacterial enzyme, 
inhibition of the brain transaminase activity was consistent 
with linear competitive inhibition when measured with GABA 
as the variable substrate, The Lineweaver-Burk plots from 
one experiment are illustrated in Fig. 6. The weighted 
average of values of the inhibition constant Kis computed 
from two such experiments was 0.58 ± 0.03 mM. This 
inhibition constant was equal to the dissociation constant 
for the reaction of 4 - aminotetro1ic acid with the pyridoxal 
form of the brain enzyme.
Glutamate decarboxylase
Brain glutamate decarboxylase in crude extracts is 
generally quite unstable - protection of the glutamate 
decarboxylase apoenzyme is always necessary for the 
maintenance of enzymic activity (Baxter, 1970). There is 
considerable disagreement on the subcellular distribution of 
the enzyme (Albers, 1960; L^vtrup, 1961; Weinstein, Roberts 
and Kakefuda, 1963; Shatunova and Sytinsky, 1964; Fonnum, 
1968). In the light of these considerations, a freshly 
prepared 10% homogenate of rat cerebral grey matter in cold 
25 mM_ pH 6.3 phosphate buffer, containing 0.2 mM_ pyridoxal 
phosphate and dithiothreitol to protect the enzyme, and 0.25% 
v/v Triton X-100 to obtain maximal activity, was found to be 
a convenient brain glutamate decarboxylase I preparation.
Both brain and bacterial glutamate decarboxylase activities 
were assayed by a radio-active method, based on that of 
Molinoff and Kravitz (1968), measuring the formation of GABA 
from glut am ate.
INHIBITION OF BRAIN
GABA AMINOTRANSFERASE 
BY 4-AMINOTETROLIC ACID
1 - 1----------  m M
GABA
Fig. 6
Analysis of data for the inhibition of brain GABA 
transaminase activity by 4-aminotetrolic acid (ATA). The 
points are means ± S.E.M. The lines represent the computed 
fit to linear competitive inhibition. Velocities (v) 
are expressed as CPM/30 min/10 mg wet tissue.
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When screened against both brain and bacterial glutamate 
decarboxylase none of the substituted tetrolic acids 
significantly influenced their activity at 1 mM.
GABA uptake
All tetrolic acids significantly inhibited the uptake 
of GABA by slices of rat cerebral cortex, with 
4-aminotetrolic acid the most potent inhibitor (Table 2).
The IC5 0  for 4-aminotetrolic acid as an inhibitor of GABA 
uptake was 450 yM.
Kinetic studies with 4-aminotetrolic acid showed that 
this acetylenic amino acid appeared to be a competitive 
inhibitor of GABA transport. Although only two different 
concentrations of inhibitor were used, the inhibition by 
4-aminotetrolic acid was consistent with linear competitive 
inhibition (Fig. 7), with a K^s of 133 ± 36 yM.
Table 2. TETROLIC ACIDS AS INHIBITORS OF GABA UPTAKE
IN RAT BRAIN CORTICAL SLICES
COMPOUNDS % INHIBITION
4-Aminotetrolicacid 55 ± 7  
4-Morpholinotetrolic acid 29 ± 7 
4-Piperazinotetrolic acid 34 ± 4 
4-Piperidinotetrol ic acid 30 ± 2 
4-Pyrrolidinotetrolic acid 36 ± 5
Rat brain cerebral cortical slices were preincubated 
with inhibitor (0.5 mM) for 15 minutes at 25°, and 
incubated for 10 minutes at 25° against 0.0125 y_M 
^H-GABA. Values are the mean (± S.E.M.) of results 
from quadruplicate experiments.
INHIBITION OF GABA UPTAKE
BY 4-AMINOTETROLIC ACID
-0 04-0 24 -020
GABA
Fig. 7
Analysis of data for the inhibition of GABA uptake by 
4-aminotetrolic acid (ATA). The points are means ± S.E.M. 
of at least 3 experimental values. The lines represent the 
computed fit to the equation v = VA/|K(1 + I/K^g) + A l f°r 
linear competitive inhibition (Cleland, 1963a,b). Units of 
v are ymol/g/min.
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DISCUSSION
Acetylenic compounds have been widely studied for 
biological activity (Schulte and Rucke, 1970).
Tremorine, oxotremorine and pargyline are perhaps the best 
known examples from a widely diverse range of 
pharmaco1oglca1ly-active compounds containing carbon-carbon 
triple bonds. The activity of such compounds may arise from 
the linear demands of the triple bond which fix the 
conformation of at least part of the molecule. The tetrolic 
acids described in the present study are analogues of 
extended conformers of GABA which may be important in some of 
the in vivo actions of this inhibitory transmitter.
All tetrolic acids depressed the firing of spinal 
neurones and could therefore interact with the postsynaptic 
GABA receptor. These acetylenic amino acids were "GABA-like" 
amino acids since bicuculline blocked the action of 
4-aminotetro1ic acid and strychnine had no effect. The 
N-substituted tetrolic acids all had weaker depressant actions 
than 4-aminotetro1ic acid, and the sterically demanding groups 
substituted at their N-terminals must considerably weaken 
their interaction at the postsynaptic receptor.
Structural similarities common to bicuculline, GABA and 
GABA-agonists have been suggested to explain the 
bicuculline-GABA antagonism (Curtis, et a 1., 1970a), and
these considerations can be extended to include 
4-aminotetro1ic acid - Fig. 8 illustrates particular 
conformations of bicuculline, GABA and 4 - aminotetro1ic acid 
in which structural similarities are apparent. When the 
carboxylate group of 4 - aminotetro1ic acid is superimposed on 
the C-C=0 grouping in bicuculline the nitrogen atoms in each
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molecule can be within 0,5 Ä of each other. For GABA and 
bicuculline the superposition of equivalent groups can be 
exact in the conformations shown, and for many other 
conformations of GABA with the absolute positions of the 
carboxylate group and nitrogen atom maintained.
The successful interaction of 4-aminotetrolic acid with 
bicucul line-sensitive postsynaptic receptors supports the 
view that GABA acts on these receptors in an extended rather 
than a folded conformation, and further supports the original 
suggestion (Curtis, et al . , 1970a) regarding the structural 
similarities of bicuculline, GABA and muscimol.
4-Aminotetrolic acid was not a substrate for either the 
bacterial or the brain transaminase. Lack of reaction does 
not stem from an inability to bind to the active sites of the 
enzymes since 4-aminotetrolic acid appears to function as a 
dead-end inhibitor, causing non-competitive inhibition of the 
activity of the bacterial enzyme and competitive inhibition 
of the activity of the brain enzyme. Transaminases, in 
general, possess only one active site which exists in either 
of two stable forms, the pyridoxal and pyridoxamine forms.
4-Aminotetrolic acid appears to bind relatively strongly to 
the pyridoxal form of both brain and bacterial enzymes, and 
this is the form with which it would bind as substrate if 
taking part in the reaction. It also appears to bind though 
less strongly, to the pyridoxamine form of the bacterial 
enzyme, but not appreciably to this form of the brain enzyme. 
Equation 1 shows, however, that the size of an intercept 
variation, indicating combination with the pyridoxamine 
form, depends on the concentration of the second substrate in 
relation to its Michaelis constant: if B J) , then no
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intercept variation will be observed even though it is 
theoretically possible for the inhibitor to combine with 
this form of the enzyme.
These findings with 4-ami notetro1ic acid confirm previous 
evidence on the different nature of the active sites of the 
brain and bacterial transaminases - for example the bacterial 
enzyme has considerably higher substrate specificity than the 
brain enzyme (Scott and Jakoby, 1959; Baxter and Roberts, 
1958). The different interactions of 4-aminotetrolic acid 
with the enzymes suggest that this linear molecule cannot 
bind to the pyridoxamine form of the brain transaminase 
because it does not interact with that part of the active 
site, which exists in this form. The N-substituted tetrolic 
acids were either very weak or non-inhibit ors of GABA 
transaminase activity, suggesting that their greater steric 
size prevented binding at the active site of the enzyme.
4-Aminotetrolic acid may represent an extended 
conformation of GABA which binds to the active site of the 
pyridoxal form of the enzyme, but cannot undergo a 
conformational change of the enzyme-substrate complex 
necessary for subsequent transamination. The inherent 
inflexible nature of the triple bond might not permit the 
enzyme: 4-aminotetro 1 ic acid complex to undergo such a 
change, and hence 4-aminotetro1ic acid functions as a 
dead-end inhibitor.
Of the substituted tetrolic acids, 4-aminotetro1ic acid 
was the most potent inhibitor of GABA uptake by rat brain 
slices. While inhibition by 4-aminotetro1ic acid was weaker 
(IC^q 450 yM_) than that of some other structural analogues 
of GABA, for example D L-2 - f luor o - GABA (IC^q 35 y_M) and
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L-2,4-diaminobutyric acid (IC^q 50 yM) (Iverson and 
Johnston, 1971), it was competitive in nature. A competitive 
inhibitor of GABA uptake into rat cerebral cortical slices 
has not been described previously, and suggests that 
4-aminotetrolic acid competes directly for the form of the 
transport carrier which binds external GABA. No information 
is available to suggest whether or not 4-aminotetrolic acid 
is in fact a substrate for the GABA uptake system. By 
comparison, muscimol, another a conformational ly restricted 
GABA analogue, was a weaker and non-competitive inhibitor of 
GABA uptake (IC^^ ca. 5000 yM) (Johnston, 1971), but had a 
stronger depressant action on the firing of spinal neurones 
than did 4-aminotetrolic acid (Johnston, et a 1 ., 1968).
The present results suggest that extended conformations 
of GABA are important in the interaction of GABA with the 
postsynaptic receptors, the active site of the GABA 
transaminase enzymes a" with the carrier which mediates 
GABA uptake. The iexible nature of GABA appears to be a 
molecular property vital to its biological activity. This 
flexibility allows GABA to adopt different "active" 
conformations when interacting with various types of receptors 
which subject the molecule to differing sets of orienting 
forces. Although an extended conformation of GABA appears to 
be the active conformation at the bicucu11ine-sensitive 
postsynaptic receptors, and extended conformations appear to 
be initially bound to the GABA transaminase active site and 
the GABA uptake carrier, other conformations of GABA are 
almost certainly necessary to achieve subsequent deamination 
and transport respectively in these two processes.
Considerable effort has been devoted to the investigation of
27
the active conformations of acetylcholine, and these studies 
with 4-aminotetrolic acid indicate similar investigations of 
active conformations of GABA are highly desirable.
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3. BICUCULLINE AND ITS MODE OF ACTION
There has been considerable speculation about the 
possible function of GABA as a mammalian inhibitory synaptic 
transmitter, and although there is much supporting evidence, 
analysis of inhibitory pathways where this amino acid could 
be the transmitter have been greatly hindered by the lack of 
a specific GABA antagonist. Indeed several systematic 
studies (Curtis, et al. , 1968a,b; Curtis and Watkins, 1965; 
Krnjevid, et a 1., 1966) have failed to reveal such an
ant agonist.
A useful GABA antagonist must possess a consistent and 
specific blocking action of mieroe1ectrophoretically 
administered GABA, and reduce the appropriate synaptic 
inhibition - picrotoxin fails to fulfil these criteria.
Largely as a result of attempts to recognise common structural 
elements of strychnine and other glycine antagonists which 
might provide a clue to structure-activity correlations 
(Batterham and Johnston, unpublished observations), several 
convulsant tetrahydroisoquino1ine alkaloids (Henry, 1949) 
were considered as potential GABA antagonists. Such alkaloids 
included bicuculline, corlumine, narcotine, hydrastine, 
laudanosine and adlumine (Figure 9), but only bicuculline was 
a selective GABA antagonist (Curtis, et al, 1970a). 
Subsequently bicuculline has been shown to reduce synaptic 
inhibition at a large number of mammalian synapses, and to be 
a relatively specific antagonist of other "GABA-like" amino 
acids. Furthermore the inhibitory effect of GABA on the 
firing of neurones in amphibians (McLennan, 1970; Woodward, 
Hoffer, Siggins and Oliver, 1971) and invertebrates (Walker, 
Crossman, Woodruff and Kerkut, 1971) is also antagonised by
bicuculline.
BICUCULLINE
CH-O
CORLUMINE
LAUDANOSINE ADLUMINE
Fig. 9
Convulsant tetrahydroisoquinoline alkaloids
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Following the discovery of this specific antagonism 
attempts were made to rationalise the bicucu11ine-GABA 
interaction on the basis of structural elements common to 
bicuculline, GABA and GABA-agonists. Since the related 
alkaloid, bicucine, possessed only weak convulsant properties 
(Welch and Henderson, 1934b) , any attempt to explain the 
bicuculline-GABA antagonism by strueture-activity 
considerations should involve the lactone ring. Examination
I
of molecular models indicated that the nitrogen atom and the 
carboxylate (0 = C - 0) grouping of GABA and agonists (or the 
equivalent N = C - 0 grouping in muscimol) could be exactly 
isosteric with the nitrogen atom and the C - C = 0 grouping 
of bicuculline in many conformations, and that all these 
substances might compete at the same postsynaptic receptor 
(Curtis, et al., 1970a). Extension of these considerations
has suggested that the bicucu11ine-sensitive GABA receptor 
recognises a conformationa1ly extended form of GABA as the 
active conformation (Beart, Curtis and Johnston, 1971).
The potent physiological action of bicuculline could 
result from another mode of biological interference, possibly 
biochemical. Bicucul1ine-induced convulsions occur because 
of the failure of certain central inhibitions, and in addition 
to the antagonism of the postsynaptic action of an inhibitory 
transmitter, might also result from the failure of 
inhibitory pathways due to a reduced release of inhibitory 
transmitter as a consequence of depleted presynaptic levels 
and/or the overactivation of excitatory pathways. GABA levels 
are likely to be controlled by the GABA transport system and 
the GABA-metabo1ising enzymes, glutamate decarboxylase and 
GABA transaminase. Inhibition of the GABA transport system
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might lead to depletion of presynaptic stores, for this 
process reconstitutes such stores (Iversen and Neal, 1968; 
Hbkfelt, et al., 1970; Bloom and Iversen, 1971; Iversen and
Johnston, 1971), while inhibition of the GABA synthesising 
enzyme, glutamate decarboxylase, or stimulation of the 
degrading enzyme GABA transaminase might also reduce GABA 
levels.
In the light of such considerations, the effect of 
bicuculline on GABA metabolising enzymes and GABA transport 
was studied to determine the exact mode of action of 
bicuculline, and structural features investigated to 
ascertain the moieties responsible for this action. 
Furthermore, when the efficacy of bicuculline as a GABA 
antagonist was questioned (Godfraind, Krnjevid and Pumain, 
1970), it was necessary to ensure that the compound 
antagonising the action of GABA was in fact bicuculline.
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RESULTS
The bicuculline used in all investigations was 
identified on the basis of elemental analysis, and was 
found to be homogenous by thin layer chromatography in three 
solvent systems. Furthermore mass, infrared and n.m.r. 
spectral data were in agreement with the proposed structure 
and previous findings (Manske, 1933; Groenewoud and 
Robinson, 1936; Edwards and Banda, 1961). The mass spectrum 
of bicuculline showed no molecular ion, and only one major 
peak at m/e 190, which can be interpreted as fragmentation 
to yield the hydrohydrastinine (1,2,3,4,-tetrahydro-6,7- 
methylenedioxy-N-methylisoquinoline) cation - a similar 
fragmentation pattern has been reported for another 
benzy1isoquino1ine alkaloid (Geliert and Summons, 1970).
Four enzymic activities were studied: glutamate 
decarboxylase from rat cerebral grey matter and from 
Escherichia coli, and GABA transaminase from rat cerebral 
mitochondria and from Pseudomonas fluorescens. Considerable 
difficulty was experienced in repeating literature 
preparations and assays for both brain enzymes, and suitable 
reproducible assays were designed for both glutamate 
decarboxylase and GABA transaminase. All enzymic activities 
were assayed by radiochemical procedures similar to those 
described by Kravitz and co-workers (1967, 1968), 
measuring the formation of GABA from glutamate by the 
decarboxylases and the coupled formation of succinate from 
GABA by transaminases. Since both assays were sensitive to 
small changes in pH, care was taken to ensure that 
bicuculline did not alter the pH of the reaction mixtures,
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and in all cases one equivalent or a very small excess of 
hydrochloric acid was used to solubilise the bicuculline.
Table 3 shows that bicuculline had no effect on the 
enzymic activities studied. The concentration of 
bicuculline employed in these investigations was well above 
the convulsive dose in mammals (ca. 0.2 mg/kg of the 
hydrochloride, Welch and Henderson, 1934a), which is 
equivalent to ca. 10  ^M, if evenly distributed in the body 
fluids. Furthermore, bicuculline did not inhibit the uptake 
of GABA by slices of rat cerebral cortex (Table 3 and 
appendix). Control slices contained 2.45 ± 0.21 ymole GABA/g 
wet tissue after 60 minutes incubation, while slices 
incubated with bicuculline contained 2.40 ± 0.12 ymole GABA/g 
wet tissue.
None of the compounds investigated (Table 4 and Fig. 10) 
could explain the bicuculline antagonism of GABA; all were 
considerably weaker or non-convulsants, and none blocked the 
inhibitory action of GABA. Salsolinol, which may be 
responsible for some of the pharmacological actions of 
alcohol (Cohen and Collins, 1970; Yamanaka, Walsh and Davis, 
1970), was a much weaker convulsant than bicuculline and had 
no effect on the depressant action of GABA or glycine. The 
related compound 6,7-dihydroxy-1,2,3,4,-tetrahydroisoquino1ine 
was only a weak convulsant - such a finding is in direct 
contrast to that of Hjert, de Beer and Fasset (1938), who 
found the LD^ was 605-670 mg/kg, and observed depression 
and terminal convulsions after injection in the anterior 
lymph sac of mice. Aminophthalidylmethane and analogues 
have been investigated as possible useful analgesics 
(Ullyott, Stehle, Zirkle, Shriner and Wolf, 1945), but this
Table 3. LACK OF EFFECT OF B1CUCULLINE ON GABA-METABOLISINC
ENZYMES AND GABA UPTAKE
Prep arat ion
Activity
Control
as % mean control 
0.1 mM bicuculline
Brain GAD I 10 0± 2(4) 10011(4)
Bacterial GAD 100±3 (4) 10112(4)
Brain GABA-T 10 0 + 4 (4) 9513(4)
Bacterial GABA-T 10015(6) 10013(6)
GABA uptake 10019(8) 9815(8)
All values are means! S.E.M. of results from the number of 
experiments shown in brackets. The enzyme preparations were 
preincubated with or without bicuculline for 5 minutes at 
37° before initiation of the reaction, the incubation 
continued for 30 minutes in the case of the brain enzymes and 
10 minutes for the bacterial extracts. The mean control 
activities were as follows: brain GAD I, 16.35 ymoles of GABA 
produced/hr/g wet tissue: bacterial GAD, 1.57 ymoles/min/mg
acetone powder: brain GABA-T, 3.26 ymoles/of succinate
produced/hr/g wet tissue: bacterial GABA-T 2.02 ymoles/min/g
acetone powder. Rat cerebral cortical slices with or without 
0.1 mfl bicuculline were preincubated for 30 minutes at 37°,
_ 14and incubated for 60 minutes at 37 against 0.1 mM GABA-1- C. 
Mean control activity was 2.45 ymoles GABA accumu1 at ed/hr/g
wet tissue.
Table 4. PHARMACOLOGICAL PROPERTIES OF BICUCULLINE ANALOGUES
ANALOGUE INTRAVENOUS INJECTION ELECTROPHORETIC 
ADMINISTRATION 
(Spinal Neurones)
Bicucu11ine 0.5mg/kg, extreme con­
vulsions almost 
immediate death, mice
blocks the action 
GABA § antagonises 
wide variety of 
central inhibition
C o r 1 urn i n e 3mg/kg, convulsions, 
rabbits (Rice, 1938)
not adequately tested, 
due to insolubility
Bicueine ca.20mg/kg, convulsions 
§ death, rabbits (Welch 
§ Henderson, 1934b)
not adequately tested, 
due to insolubility
Adlumine 1 00 - 125mg/kg, convul­
sions, rabbits (Welch 
§ Henderson, 1934a)
not adequately tested, 
due to insolubility
Hydrastine 2 0mg./kg, convulsions, 
rabbits (Welch § 
Henderson, 1934a)
not adequately tested, 
due to insolubility
Narcotine 20-25mg/kg, c h r o n i c  
convulsions, cats 
(Cooper § Hatcher, 1934)
no action
Laudanosine 6-12mg/kg, convulsions, 
cats (Delphaut, 1934)
blocks the action of 
glycine not GABA, and 
reduces strychnine- 
sensitive inhibition 
(Curtis, et al., 1970a)
Bicucu11ine 
d io 1
75mg/kg, chronic con­
vulsions § death, mice
no action against 
glycine or GABA
Salsolinol 50-100mg/kg, chronic 
twitches § death, mice
depressant action, no 
action against GABA
6,7-Dihydroxy- 
1,2,3,4,- 
tetra-hydro- 
isoquinoline
100mg/kg, chronic 
twitches § death, mice
not tested
Aminophtha- 
1idylmethan e
100-150mg/kg i.p., no 
analgesic activity, cats 
(Ullyot et al., 1945)
depressant action, no 
action against GABA
— OH
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Bicuculline and analogues
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compound exhibited no properties comparable with bicuculline 
- in fact it depressed the firing of spinal interneurones 
and did not antagonise the action of GABA. Reduction of the 
lactone ring considerably reduced the convulsant action of 
bicuculline and completely removed the antagonism of GABA. 
Bicuculline diol was a weak depressant of neurones and had 
no effect on electrophoretic GABA or glycine.
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DISCUSSION
The finding that bicuculline was a specific antagonist 
of the depressant action of GABA strongly supported existing 
evidence for GABA as an inhibitory transmitter in the 
mammalian central nervous system. Bicucu11ine ' s mode of 
action was considered to be a postsynaptic block of inhibitory 
synaptic transmission, and the present results show that the 
bicucu11ine-induced convulsions are unlikely to result from 
effects on the GABA-metabolising enzymes, glutamate 
decarboxylase and GABA transaminase, or the GABA uptake 
system. These findings are not unexpected in view of the 
fact that bicuculline-induced convulsions and death are very 
rapid (of the order of seconds) when a lethal dose of the 
alkaloid is administered. Any effects at the metabolic level 
would probably result only after a longer period of time 
(minutes) necessary to change a particular metabolite 
concentration - e.g. convulsions due to the inhibition of 
glutamate decarboxylase by allylglycine are only observed 
after 2-2y hours (Alberici, Arnaiz and de Robertis, 1969).
Histological studies on GABA transaminase activity in 
the guinea pig brain stem are in agreement with the present 
findings that GABA transaminase activity is unaffected by 
bicuculline, even though the alkaloid was employed as the 
free base in aqueous dimethyl sulphoxide (Davies and Comis, 
1971). Recently bicuculline has been shown by other workers 
not to significantly inhibit the GABA uptake system into 
rat brain cerebral cortical slices (Iversen and Johnston,
1971; Johnston and Mitchell, 1971). Clearly the postsynaptic 
action of GABA and its transport system are very different 
processes, since bicuculline does not influence the transport
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system and apparently antagonises postsynaptic action, while 
p-ch1oromercuriphenylsulphonate antagonises the transport 
system (Iversen and Johnston, 1971), and also potentiates the 
postsynaptic action of GABA (Curtis, et al . , 1970b).
Recently the efficacy of bicuculline as a GABA 
antagonist has been questioned (Godfraind, et al., 1970;
Straughan, Neal, Simmonds, Collins and Hill, 1971), but these 
objections seem ill-founded. Straughan, et a 1. , (1971) found
that bicuculline, in addition to blocking the inhibitory 
action of GABA, also accelerated the rate of onset of 
inhibition, weakly inhibited GABA transaminase activity in 
vitro, but not in vivo, without affecting glutamate 
decarboxylase activity, and decreased the rate of 
disappearance of H-GABA (i.e. the rate of GABA turnover) 
from the brain. The weak inhibition of GABA transaminase 
was probably due to the fact that the concentration of 
bicuculline employed (1 mM) can only be obtained with 
higher concentrations of mineral acid, which would shift the 
pH from the optimal pH of the enzyme, with resulting loss in 
activity. The effect of bicuculline on GABA turnover is more 
difficult to explain, but may be related to decreased 
synaptic activity under the influence of bicuculline and 
hence a reduced requirement for GABA, accompanied by a 
decreased GABA turnover. Bicuculline (0.01 mM) increased
3the electrically evoked release of H-GABA from rat brain 
cortical slices in vitro and in vivo (Johnston and Mitchell, 
1971) - this increased in vitro release occurred only at
0.01 mM_, and resulted in a 70% increase of GABA at peak 
efflux and a 40% total increased GABA release. There appears 
to be no simple answer to this observation, further
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emphasising the complex nature of such release studies 
(Curtis and Johnston, 1970), Bicucu11ine-induced convulsions 
appear not to result from inhibition of the activity of the 
GABA-met aboilsing enzymes or GABA uptake.
The activity of bicuculline as a GABA antagonist was 
clearly dependent on the maintenance of its structural 
integrity. No particular part of the molecule seemed 
responsible for the specific blocking action of bicuculline, 
for neither the tetrahydroisoquinoline nor the phthalidyl 
moieties possessed outstanding pharmacological properties.
The lactone ring was essential for activity - when destroyed 
the molecule lost its precise configuration and its specific 
mode of action. Both bicuculline diol and bicucine had no 
effect on the inhibitory action of GABA. Although structural 
similarities exist between bicuculline, GABA and GABA 
agonists (Curtis, et a 1., 1970a; Beart, et al . , 1971) and the 
lactone ring is vital to these considerations, other 
substituents are also important and minor modifications in 
the molecule reduce the particular action of bicuculline. 
Corlumine, which has the 6,7-methy1ene dioxy bridge converted 
to 6,7-dimethoxy groups, was a potent convulsant (3 mg/kg), 
but no action could be demonstrated on spinal neurones.
This bridge may be concerned with the establishment of 
stabilising interactions at the postsynaptic receptor. 
Furthermore tetrahydroisoquinoline alkaloids with potent 
convulsant properties, but different configurations to 
bicuculline, were glycine antagonists rather than GABA 
antagonists. Polar groups are generally essential for 
binding to a receptor, and a peculiar property of bicuculline 
is that all such groups are held in a fixed configuration,
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suggesting their involvement in a number of specific 
interactions in the action of bicuculline at the postsynaptic 
receptor, so that GABA is somehow prevented from exerting its 
hyperpolarising action. This particular ability of 
bicuculline to antagonise the postsynaptic action of GABA 
seems to result from a combination of factors, and very 
precise studies will be required to establish the molecular 
action of bicuculline at the synaptic level.
38
4„ GABA TRANSPORT IN RAT CEREBRAL CORTEX
Uptake, rather than enzymic inactivation, represents 
a plausible mechanism for the termination of the 
postsynaptic action of GABA at mammalian central synapses, 
and also an efficient concentrating process for the 
reconstitution of presynaptic stores of GABA (Curtis and 
Watkins, 19 65; Iversen and Neal, 1968; Curtis and Johnston, 
1970; Curtis, et al., 1970b).
The accumulation of GABA has been demonstrated in a 
variety of mammalian brain tissue preparations (Sano and 
Roberts, 1963; Weinstein, et al., 1965; Varon, et al., 1968; 
Iversen and Neal, 1968; Navon and Lajtha, 1969; Hbkfelt, 
et al., 1970; Gottesfeld and Elliott, 1971; Iversen and
Johnston, 1971) and exhibits inhibition patterns and 
substrate specificity p r o p e r t i e s  which are very similar to 
those for GABA uptake by the crustacean nerve-muscle 
preparation (Iversen and Kravitz, 1968).
Important features of the GABA transport system are the 
ability to accumulate GABA to high tissue to medium ratios 
(Iversen and Neal, 1968), the high specificity for the GABA 
skeleton with its zwitterionic centres (Iversen and Neal, 
1968; Iversen and Johnston, 1971), the identification of 
nerve ending particles as the sites of uptake (Hbkfelt, 
et al., 1970; Iversen and Johnston, 1971), the localisation 
of accumulated GABA in nerve endings (Bloom and Iversen, 
1971), and the correlation of the density of uptake sites 
with the distribution of synapses at which GABA is the 
likely inhibitory transmitter (Hbkfelt, et a 1., 1970;
Iversen and Johnston, 1971).
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Studies with 2-fluoro-GABA and L-2,4-diaminobutyric acid 
as inhibitors of GABA uptake suggest that substituents on 
carbon 2 appreciably influence the transport of GABA by the 
carrier. A number of other structural modifications of GABA 
for example replacement of carbon 4 and the amino group by a 
guanidino or hydrazino group, result in substances whose 
potency as inhibitors of GABA transport system is somewhat 
reduced (Iversen and Johnston, 1971). Since the GABA 
transport process is so structurally specific it may also be 
conformationally specific. The aims of this study were to 
further investigate the influence of GABA analogues, 
particularly 2 - substituted analogues and analogues of 
restricted conformation, on the GABA uptake system, and to 
continue the search for a pharmacologically useful inhibitor 
of GABA uptake.
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RESULTS
A total of 83 compounds, including 53 GABA analogues, 
were screened against the GABA uptake system in rat brain 
cerebral slices. Initially only a single concentration of 
a drug was employed, but marked inhibition of the uptake 
process was further investigated by the determination of 
IC5Q values (concentration of inhibitor giving 50% inhibition 
under the conditions employed), and if of importance kinetic 
aspects of the inhibition. A substrate for a particular 
transport system will effectively inhibit the observed uptake 
of the natural substrate of the transport system when present 
in sufficient molar excess to overcome differences in the 
affinity of the two substrates for the transport system: 
thus putative substrates can be rapidly screened and an 
assessment made of the possible substrate specificity. Since 
the concentration of (^H-)GABA was 0.0125 yM_ the test substance 
was always present in large molar excess. The results 
obtained fall into several classes.
(1) 2 - Substituted GABA analogues
GABA transport was markedly influenced by GABA analogues 
substituted in the 2-position (i.e. a-substituted) - all 
those investigated, except 2-ureido-GABA, were potent 
inhibitors (Table 5A) . The potency of 2-fluoro-GABA was 
confirmed (Iversen and Johnston, 1971), and 2-bromo-GABA, the 
most potent of the 2 - substituted-GABA analogues investigated, 
was of comparable potency to the most potent inhibitor of 
GABA uptake, 4-aminovaleric acid ("4-methy1-GABA") .
(2) N-Substituted GABA analogues
Most of the N-substituted GABA analogues were inhibitors 
of the GABA transport system (Table 5A). The inhibitions
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observed with N-formyl, N-acetyl and N- 1aury1-GABA, which are 
all molecules without a formal positive charge on the N 
terminal, appear to be directly opposed to predictions that 
both zwitterionic centres are necessary for binding to the 
transport carrier, but suggest there may be sufficient 
positive charge on the N atoms for a stabilising interaction 
to occur with the binding site for uptake. Roberts and Sano 
(1963) found N-methyl, N-formyl and N-acety1-GABA all 
inhibited the binding of GABA to particulate fractions, but 
their inhibitions were always much lower than those observed 
in the present study - indeed N-me thy 1 - GAB A (IC50 23yM) was a 
particularly potent inhibitor of GABA uptake.
(3) Sulphur containing GABA analogues
Homohypotaurine, a molecule with very similar physical 
properties to those of GABA, was apparently recognised in a 
very similar manner to the natural substrate, and was a 
strong inhibitor of GABA uptake. A rationale of the 
contrasting results obtained with the other sulphur 
containing GABA analogues seems difficult, but clearly the 
increased acidity of these sulphonic and sulphuric acids 
relative to GABA and homohypotaurine must considerably reduce 
their influence on the transport process (Table 5A) .
(4) Conformationally restricted GABA analogues
Among the conformationa1ly restricted amino acids
(Table 5B) only trans-4 - aminocrotonic acid, 
cis-3-aminocyclohexanecarboxylie acid and 4-aminotetro1ic 
acid were strong inhibitors of the GABA transport system, 
and analysis of inhibitions by these substances provided 
useful information about the nature of the active GABA 
conformation essential for binding to the carrier involved.
4-Aminotetro1ic acid (ATA) has already been discussed in 
detail and is a linear competitive inhibitor of GABA uptake 
(IC50 450yM, K^s 133y_M)„ C i s - 3 - amin 0 cy c 1 oh exane carboxy 1 i c 
acid and trans-4-aminocrotonic acid were also competitive 
inhibitors - IC50 85 and 26yM, Kis 100 and 8 yM 
respectively (Table 6, Figs, 11 and 12). The corresponding 
trans - 3-amino eye 1 ohexane carboxylic acid was only a very 
weak inhibitor of GABA uptake (IC^q 140 OyM) .
(5) Miscellaneous GABA analogues
IC^q determinations revealed 4-aminovaleric acid 
(ICj-q 3 yM) as the most potent inhibitor of GABA uptake of 
the substances investigated (Table 5C). Comparison with the 
apparent IC^q for ’’cold" GABA (15 _yM) and those of other 
potent GABA analogues, demonstrated 4-aminovaleric acid and
2- bromo-GABA were more potent by approximately an order of 
magnitude.
The carbonyl group, rather than the carboxylate anion 
may be more important for binding involved in uptake 
(Roberts and Sano, 1963), and the inhibition of GABA 
transport observed with the GABA methyl ester may support 
this suggestion. This suggestion was based on inhibitions 
found with the hydroxamic acid and the isopropyl ester of 
GABA, and may also explain the inactivity of GABA amide and
3- aminopropane boronic acid, in which the nature of the 
carbonyl group has been radically changed or the group has 
been removed, respectively. Furthermore cyclization of GABA 
to pyrrolidin-2-one completely abolished the ability to 
inhibit the uptake process.
GABA-choline, which has been suggested as an alternative 
inhibitory transmitter to GABA (Howells, 1971), was a very 
weak inhibitor of GABA uptake (IC^^ 2900yM).
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(6) Drugs screened against the GABA uptake system
The majority of drugs were screened at O.lmM, but due to 
solubility problems some of the antibiotics were tested at 
lyg/ml (Table 5D).
Table 5A. INHIBITION OF GABA UPTAKE BY GABA ANALOGUES
ANALOGUE % INHIBITION lC5o(yM)
2-Substituted GABA analogues
2-bromo-GABA 9 9 ± 0.5 4
2-hydroxy-GABA 86±0 . S 20
2 -fluoro- GABA 95 36
2 -ch1oro-GABA 85 ±0.5 59
2-methyl-GABA 79 ±1 77
2 -oxo- GABA 66±2
2-ureido-GABA -
Substituted GABA analogues
N-methy1-GABA 8 2 ± 1 23
N- formyl- GABA 72 + 1 100
N-acety 1 - GABA 33±2
N-1aury1- GABA 2 6±6
4-butyrobetaine 2 5 ± 3
N,N-dimethyl-GABA
Sulphur containing GABA analogues
homohypotaurine 85±1 34
2-gaunidinoethanethiosulphonic acid 42±6
2- aminoethane sulphuric acid 36±5
3- aminopropane sulphonic acid 20±5
2-aminoethanethiosulphonic acid
Table 5B. INHIBITION OF GABA UPTAKE BY GABA ANALOGUES
ANALOGUE % INHIBITION IC50(yM)
Con formationally restricted GABA analogues
trans - 4-amino crotonic acid 9 9 ± 1 26
cis- 3-aminocyclohexane carboxylie acid 84±2 85
4-aminotetro1ic acid 5 5 ± 7 450
transexamic acid 2 5 ±2
ethyl piperidine-4-carboxylate 2 3±2
trans-3-aminocyclohexanecarboxylic acid 20±4 1400
piperidine - 4-carboxy1ic acid 20 ± 1
Analogues without significant inhibition
2- amino,2-aminomethylcyclohexanecarboxylic acid, 
cis-2-aminocyclohexanecarboxylic acid,
trans - 2 - aminocycl oh exane carboxylic acid, 
p-aminomethylbenzoic acid,
L-azetidine-2-carboxylic acid, 
cisexamic acid,
D-glucosaminic acid, 
is onicotinic acid, 
piperidine-4-carboxamide,
3- pyridineacetic acid.
Table 5C. INHIBITION OF GABA. UPTAKE BY GABA ANALOGUES
ANALOGUE % INHIBITION ic50(yM)
Miscellaneous GABA analogues 
4-aminovaleric acid 93±0.5 3
GABA methyl ester 3 4±6
oxaluric acid 32 ±5
GABA-choline 20 2900
N - (2-imidazoylinyl)-glycine 1 9±4
formimidoylglycine 9 ± 1
Analogues without significant inhibition
GABA amide, 2-aminoheptane, 3-aminopropane boronic acid, 
n4-aminoxy-GABA", l-acetamidopyrrolidin-2-one, crotonic 
acid, glycy1-GABA,2-guanidino-2-pheny1acetic acid, 
4-hydroxypyrrolidin-2-one, pyrrolidin-2-one, ureidoacetic 
acid, ureidooxyacetic acid.
Rat brain cerebral cortical slices were preincubated with 
inhibitors (0.5 mM) for 15 minutes at 25°, and incubated for 
10 minutes at 25° against 0.0125 y_M ^H-GABA. Values are the 
mean (± S.E.M.) of results from quadruplicate experiments. 
Unless otherwise stated all inhibitors were DL mixtures.
The inhibitions by 2-fluoro-GABA and GABA-choline at 
0.5 mM were determined from "IC^q lines” .
IC^q - the concentration of inhibitor giving 50% 
inhibition of GABA uptake under the above conditions.
Table SD,
THE INHIBITION OF GABA UPTAKE BY MISCELLANEOUS DRUGS
COMPOUND (0,1 mM) % INHIBITION
Protoveratrine A 78±1
Protoveratrine B 66±2
Strophanthidin 65±9
Jug lone 57±10
2,4-Dinitrophenol 42±7
S 2017 42± 2
Ch1oroamphenico1 35±2
N^,0^-dibutyry1-31,5 * - cyclic AMP 34±1
Amiloride 28±5
Drugs without significant effect at 0.1 mM
Adamantidine, 5-Azaindole, Bulbocapnine, 3',5f-cyclic AMP, 
Cycloheximide, Cocaine, DL-Coniine, Hemicholinium 3, 
Puromycin, Reserpine, Sernyl, S 1574, S 2428, S 1694,
S 1976 and Nialamide (0.5 mM) .
Drugs without effect at 1 yg/ml
Antimycin A, Gramicidin D, Mitomycin C, Oligomycin,
V alinomycin.
Rat brain cerebral cortical slices were preincubated 
with drugs of the appropriate concentration for 15 
minutes at 25°, and incubated at 25° against 0.0125 y_M
3H-GABA as for the screening of the GABA analogues. 
Values are the mean (± S.E.M.) of results from 
quadruplicate experiments.
Table 6 . INHIBITION CONSTANTS FOR THE INHIBITION OF 
GABA UPTAKE BY SOME GABA ANALOGUES
Analogue Type of 
inhibition
inhibition 
constants (yM)
trans-4-aminocrotonic parabolic K . . 20.1±11 . 5 11
acid competitive K .0 2 5.8 ±2 3.0 12
linear K. 8.3 ± 2.01 s
competitive
cis-3-aminocycIohexane- linear K. 10 0± 2 21 s
carboxylic acid competitive
4-aminotetrolic acid linear K . 133±36is
competitive
The values for the inhibition constants ± S.E.M. were 
computed from the experimental data fitted to the type of 
inhibition indicated. The nomenclature is that of
C1eland (1963 a,b) .
INHIBITION OF GABA UPTAKE
BY TRANS 4-AMINOCROTONIC ACID
250-
-0 24 -0 20 -016-0 28 -0 08 -004
GABA
Fig. 11
Analysis of data for the inhibition of GABA uptake by 
trans-4-aminocrotonic acid (ACA). The points are means ± S.E.M. 
of at least 3 experimental values. The broken lines represent 
the computed fit to the equation v = VA/|K(1 + I/K^s) + A l f°r 
linear competitive inhibition and the solid lines the fit to 
the equation v = VA/|K(1 + I/K.^ + I2/Ki;L Ki2) + A| for 
parabolic competitive inhibition (Cleland, 1963a,b). Units 
of v are ymol/g/min.
INHIBITION OF GABA UPTAKE
CIS-3-AMINO-CYCLOHEXANE-
CARBOXYLIC ACID
-008 - 0.04
GABA
Fig. 12
Analysis of kinetic data for the inhibition of GABA 
uptake by cis-3-aminocyclohexanecarboxylic acid(CIS). The 
points are means ± S.E.M. The lines represent the computed 
fit to the equation for linear competitive inhibition.
Units of v are ymol/g/min.
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DISCUSSION
The specificity of the GABA uptake system undoubtedly 
ensures that other metabolites are not transported by this 
process, and hence do not interfere with the vital role of 
the transport system in maintaining and reconstituting GABA 
pools in the central nervous system. Studies with a wide 
range of GABA analogues emphasise the high specificity of 
this uptake system for the GABA skeleton, orientated in its 
active conformation, with the amino and carboxyl groups the 
"correct" distance apart in the right state of ionisation. 
Clearly a slight modification of any one of these "criteria" 
reduces the interaction of the molecule with the membrane 
transport carrier.
IC[-q determination involves estimation of the inhibition 
of uptake in the presence of a constant GABA concentration by 
varying concentrations of an inhibitor. Hence an IC^ value 
is a measure of the concentration dependence of the 
inhibition produced by certain drugs, or the tightness of 
binding of a particular inhibitor to the transport carrier. 
Several 2-substituted and conformationally restricted GABA 
analogues, which were potent inhibitors of uptake, possessed 
inhibitions whose concentration dependence were remarkably 
similar (i.e. the lines used to determine their IC^ -q values 
had very similar slopes) (Figs. 13 and 14). Such a finding 
might be coincidental, but suggested there may be a 
relationship between the concentration dependence of an 
inhibition as found from an IC^ determination, and the 
kinetic nature of the inhibition, evaluated by varying the 
GABA concentration at constant inhibitor concentrations.
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INHIBITOR CONCENTRATION M
Fig. 13
Determination of ICC(. values of 2-substituted GABADU
3analogues as inhibitors of H-GABA uptake in slices of rat
3brain. Each point is the mean of 4 determinations. H-GABA 
uptake, expressed as per cent control, is plotted on 
probability scale against inhibitor concentration on a log 
scale. CHLORO, HYDROXY, METHYL, FLUORO and BROMO are all 
GABA analogues with these moieties substituted in the 
2 positions.
TRANS
- 2
Fig. 14
Determination of ICrri values of conformationallyo U
3restricted GABA analogues as inhibitors of H-GABA uptake 
in slices of rat brain. Each point is the mean of 4
3determinations. H-GABA uptake, expressed as per cent 
control, is plotted on a probability scale against inhibitor 
concentration on a log scale. ACA = trans-4-aminocrotonic 
acid, CIS = cis-3-aminocyclohexanecarboxylic acid, ATA = 
4-aminotetrolic acid and TRANS = trans-3-aminocyclohexane- 
carboxylic acid.
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Indeed, since trans-4-aminocrotonic acid,
cis-3-aminocyclohexanecarboxylie acid and 4-aminotetrolic 
acid were all competitive inhibitors, these 2-substituted 
analogues may also inhibit GABA uptake in a competitive 
fashion. By contrast, both 2-fluoro-GABA and
L-2,4-diaminobutyric acid were non-competitive inhibitors of 
GABA uptake (Iversen and Johnston, 1971). The inhibition by 
2-fluoro-GABA of GABA uptake was considerably more 
concentration dependent (Fig. 13) than inhibition by the 
other 2-substituted GABA analogues, suggesting a different 
mode of inhibition.
Competitive inhibitors of GABA uptake have not been 
previously described - this mode of inhibition would involve 
direct competition with GABA for the carrier. No 
information is available as to whether or not these inhibitors 
were substrates for the GABA transport system.
4-Aminotetrolic acid was a linear competitive inhibitor of 
GABA uptake, but the nature of the inhibition was less clear 
cut with trans - 4-aminocrotonic acid and 
cis-3-aminocyclohexanecarboxylie acid. While 
trans-4-aminocrotonic acid was definitely a competitive 
inhibitor of GABA uptake, the results were always more 
consistent with parabolic rather than linear competitive 
inhibition i.e. a doubling of inhibitor concentration more 
than doubled the slope of the double reciprocal plot 
(Fig. 11). Parabolic competitive inhibition could result 
from the binding of more than one molecule of the inhibitor 
to the same form, of the carrier. This form of the carrier 
would be that which bound extracellular GABA, although the 
linearity of the double reciprocal plot of GABA uptake versus
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GABA concentration indicated that this form of the carrier 
bound only one molecule of GABA. Alternatively parabolic 
competitive inhibition could result from the involvement of 
more than one binding site in the interaction of the 
inhibitor with the carrier. The inhibition of GABA uptake by 
cis-3-aminocyclohexanecarboxy1ic acid could be fitted to both 
linear competitive and non-competitive inhibition, but was 
more consistent with linear competitive inhibition (Fig. 12).
Although no simple relationship can exist between the 
inhibition constants computed from the kinetic data, and 
dissociation constants for the binding of a substrate 
analogue to the carrier, these inhibition constants allow the 
affinity of a series of analogues for the active site(s) to 
be compared, and hence speculation about how closely a 
particular analogue approximates the natural substrate and 
its active conformation recognised by the transport carrier.
Zwitterionic centres are almost certainly essential for 
the binding of an inhibitor (or substrate) to the active 
site. Their stabilising interactions with the carrier 
active site are probably influenced by both the state of 
ionisation and the distance between the zwitterionic centres 
(Table 7 and Fig. 15). The most potent conformationally 
restricted analogue, trans-4-aminocrotonic acid, was a 
slightly stronger acid than GABA and its zwitterionic 
centres cannot be less than 4.9Ä apart.
Cis-3-aminocyclohexanecarboxylic acid was an order of 
magnitude weaker than trans-4-aminocrotonic acid as an 
inhibitor, but is a more flexible molecule with pK values 
closer to those of GABA. It is a GABA analogue bearing 
substituents on carbons 2 and 4, and the present study has
Table 7. SOME PROPERTIES OF GABA AND SOME
CONF ORMATIONALLY RESTRICTED GABA ANALOGUES
pK values N to 
max
0 distance in Ä 
. min.
GABA 4.04, 10.71 6.2 less than 1.5
trans-4-amino crotonic 
acid
3.55, 9.36 6 . 1 4.9
cis-3-aminocyclohexane- 
carboxylic acid
3.70, e, e, 
a,a,
6.2 
3.9
4.8
less than 1.5
4-aminotetrolic acid 1.80, 8.34 5 . 8 5.2
t rans - 3-amino- 
cyc1ohexane 
carboxylic acid
3.85, 5.4 4.7
The pK values were determined at 20° for GABA by King (1954), 
trans - 4-aminocrotonic acid and 4-aminotetrolic acid in the 
present study, and for the cyclohexane derivitatives by Hewgill 
and Jefferies (1955). N to 0 distances were estimated by 
measurements on Drieding stereomodels.
GABA
(fully extended)
♦ x h 2-c=c-co2
trans-4-aminocrotonic acid 4-aminotetrolic acid
HoN
cis-3-aminocyclohexane- 
carboxylic acid
(diaxial) (diequatorial)
trans-3-aminocyclohexane- 
carboxylic acid
Fig. 15
Structures of GABA and some GABA analogues of 
restricted conformation that inhibit GABA uptake in slices 
of rat brain. Only chair conformers of the cyclohexane 
derivatives are shown.
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revealed strong inhibitors bearing substituents on these 
carbons (namely "4-methyl-GABA" and 2-bromo-GABA). There is 
some evidence to suggest that cis-3-aminocyclohexanecarboxylic 
acid may exist in the diequatorial form in solution (Hewgill 
and Jefferies, 1955), with the zwitterionic centres 4.8 - 6.2Ä 
apart in an extended conformation. The weaker inhibition 
observed with cis-3-amino eyelohexanecarboxylic acid may result 
from the cyclohexane ring interfering with the binding to the 
carrier. 4-Aminotetro1ic acid was also a weaker inhibitor of
GABA uptake than was trans-4-aminocrotonic acid, but this 
amino acid was a much stronger acid than trans-4-aminocrotonic 
acid or GABA. A similar explanation probably accounts for the 
stronger inhibition by 3-aminopropane sulphinic acid of GABA 
transport relative to that observed with 3-aminopropane 
sulphonic acid. The only other conformationally restricted 
GABA analogue investigated in any detail is the psychoactive 
isoxazole, muscimol (Johnston, et al., 1968; Kier and Truitt,
1970; Johnston, 1971). This analogue is only a weak 
inhibitor of GABA uptake (IC^q ca. 5000yM) (Johnston, 1971) - 
the state of ionisation (pK values 4.78 and 8.43; Eugster, 
1969) and the planar nature of the rigid isoxazole ring must 
greatly reduce binding to the carrier.
Among the drugs screened against the transport system, 
the veratrine alkaloids, protoveratrine A and B, were found 
to be strong inhibitors. These alkaloids apparently 
interfere with sodium ion movements by stabilising the 
sodium-ion-selective channels, once they have been formed 
(Baker, 1968), but act at different sites to ouabain and do 
not effect the sodium/potassium dependent ATPase (Yoshida, 
Kaniike and Namba, 1963). Recently GABA uptake into slices
48
has been suggested to involve first a sodium ion dependent 
binding, and then a transfer from the binding site to an 
"occluded" pool, and that protoveratrine exerts its 
inhibitory effect by blocking this sodium dependent binding 
(Gottesfeld and Elliott, 1971). The veratrine alkaloids 
appear to be of limited use as pharmacological agents as they 
are non-specific inhibitors of uptake, and also reduce the 
transport of glycine, glutamate and aspartate (Balcar, Beart 
and Johnston, unpublished observations), and dopamine 
(Yoshida, et a1., 1963). Strophanthidin, an aglycone 
structurally related to ouabain, mimics the action of this 
steroidal glycoside and blocks active sodium ion transport in 
a variety of preparations (Johnson, 1956; Orloff and Burg,
1960; Glynn, 1964; Horowicz and Gerber, 1965; Brinley, 1968; 
Brinley and Mullins, 1968; Sokolove and Cooke, 1971). 
Furthermore there appear to be both strophanthidin-sensitive 
and insensitive sodium ion fluxes (Horowicz and Gerber, 1965). 
Although strophanthidin was a strong inhibitor of GABA 
transport into rat cerebral cortical slices, it appears to 
antagonise other amino acid transport systems (Balcar, Beart 
and Johnston, unpublished observations). In contrast, 
amiloride a potent inhibitor of sodium transport across the 
toad bladder (Bentley, 1968; Gatzy, 1971; Cuthbert and Wong, 
1971), was only a weak inhibitor of GABA uptake.
GABA accumulation against a concentration gradient is an 
active process (Iversen and Neal, 1968), and hence is 
inhibited by a variety of oxidative phosphorylation inhibitors 
- juglone, 2,4-dinitropheno1 and chloramphenicol. Juglone, a 
potent CNS depressant isolated from walnut shells (Westfall, 
Russell and Auyong, 1961; Auyong, Russell and Westfall, 1963),
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was the best inhibitor of GABA uptake giving 57% inhibition 
at 0.1 mM, but is unsuitable as a pharmacological tool because 
of its insolubility, instability and non-specificity (Balcar, 
Beart and Johnston, unpublished observations). Other 
inhibitors of electron transport (antimycin A, gramicidin I) 
valinomycin and oligomycin), which apparently influence ion 
movements (Lust and Robinson, 1970a,b), were all inactive 
against the GABA transport system - the concentration employed 
might be too low to produce any effect on uptake.
The outstanding feature of the GABA uptake system is its 
specificity. Considerable further kinetic studies of the 
inhibition patterns of substrate analogues are necessary to 
investigate the nature of the interactions essential to the 
formation of the substrate-carrier complex for transport, and 
the number of binding sites involved, in the hope that the 
factors responsible for the specificity of the transport 
system may be completely elucidated. Furthermore so little 
is known about the carrier involved, it chemical nature and 
active conformation, or the binding of the substrate and 
whether a particular conformation is necessary for initial 
recognition by the carrier and another lipophilic 
conformation for transport across the membrane, that much 
effort must be directed towards these basic problems. So far 
no pharmacologically useful inhibitor of GABA uptake process 
has been revealed, but such an inhibitor might be extremely 
useful in attempts to evaluate the physiological role of the 
GABA uptake system and to isolate the uptake carrier.
Ill AN ISOXAZOLE ANALOGUE OF GLYCINE
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1. GENERAL INTRODUCTION
Glycine, the first amino acid isolated from protein, has 
a ubiquitous occurrence in tissue, and moderate amounts are 
unevenly distributed in vertebrate nervous tissue (Tallan, 
1962; Shaw and Heine, 1965; Kandera, Levi and Lajtha, 1968; 
Aprison, Shank and Davidoff, 1969). Although the simplest 
amino acid, little is known about its intermediary metabolism 
- possibly because the molecule can undergo many diverse 
reactions due to its simple two carbon skeleton. In addition 
to its widespread occurrence and its involvement in 
metabolism, recent evidence suggests that glycine may also 
play a role as an inhibitory transmitter at certain synapses 
in the mammalian central nervous system.
Early pharmacological investigations of amino acids 
structurally related to GABA revealed that glycine topically 
applied to the cerebral cortex (Purpura, et a1., 1959) and
electrophoretically administered near spinal neurones 
(Curtis and Watkins, 1960) depressed the activity of central 
neurones. Further, glycine decreased the reflex activity 
of the amphibian spinal cord in situ (Fukuya, 1961) and in 
vitro (Curtis, Phillis and Watkins, 1961), but did not effect 
the activity of either the crayfish stretch-receptor 
(Edwards and Kuffler, 1959) or the nerve-muscle preparation 
(Robbins , 1959) .
Glycine distribution
In the light of these studies glycine was considered as 
a putative spinal inhibitory transmitter in its own right. 
Spinal inhibition is mediated through relatively short axon 
interneurones, and afferent fibres entering the cord in the
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dorsal roots are excitatory, hence the inhibitory transmitter 
(and possibly its synthesising enzymes and biological 
precursors) might be concentrated in the grey matter and 
possibly also the propriospinal fibres in the white matter. 
Glycine has such a distribution in the spinal cord (Aprison 
and Werman, 1965). Furthermore, temporary aortic occlusion 
which results in a loss of interneurones in the central 
region of the cord, decreases spinal glycine levels while 
there is no significant change in those of GABA (Davidoff, 
Graham, Shank, Werman and Aprison, 1967). Regional levels of 
glycine in mammalian supraspinal regions are highest in the 
pons-medulla, being twice that in the midbrain and more than 
three times that in cerebral hemispheres and cerebellum (Shaw 
and Heine, 1965; Kandera, et al., 1968; Aprison, Shank and 
Davidoff, 1969), and suggest an inhibitory transmitter role 
for glycine in the pons-medul1 a, as well as in the spinal cord.
Postsynaptic action
Glycine hyperpolarises spinal motoneurones (Werman, 
Davidoff, and Aprison, 1967 $ 1968; Curtis, et al., 1968b) and 
interneurones (Bruggencate and Engberg, 1968), and cortical 
neurones (Curtis, Hösli and Johnston, unpublished 
observations). When administered electrophoretically glycine 
is generally a more potent depressant than GABA of spinal 
interneurones and motoneurones (Curtis, et al., 1968a,b;
Werman, Davidoff and Aprison, 1966), and of brain stem 
neurones (Hösli and Tebecis, 1970), approximately equipotent 
upon Renshaw cells (Curtis, et a1., 1968a) and cuneate 
neurones (Galindo, Krnjevic and Schwarz, 1967), but less 
potent on cortical neurones (Krnjevib and Phillis, 1963;
Curtis, et a1 ., 1968a; Kelly and Krnjevid, 1968 § 1969;
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Johnson, Roberts and Straughan, 1970), These regional 
differences may indicate the relative distribution of 
postsynaptic receptors at which glycine and GABA act as 
inhibitory transmitters.
Glycine antagonists
Strychnine antagonises a wide variety of spinal, and 
some supraspinal inhibitions (Curtis, 1963), and reversibly 
suppresses the hyperpolarization of spinal motoneurones by 
glycine, without affecting that produced by GABA (Curtis, 
et a 1 . , 1968b). Furthermore strychnine administered
e 1 ectrophore11 ca 11y blocks the inhibitory action of glycine 
on neurones of spinal, cord (Curtis, et a 1 , , 1968a,b; Larson,
196 9; de Groat, 1970), cerebral cortex (Curtis, et a 1 . , 19 68a;
Johnson, et a 1 . , 1970), oculomotor nucleus (Obata and
Highstein, 1970), brain stem (Hösli and Tebecis, 1970),
Deiters’ nucleus (Bruggencate and Engberg, 1969) and cuneate 
nucleus (Galindo, 1969). However, ther are many strychnine- 
insensitive inhibitions e.g,, inhibition of Deiters' nucleus 
by cerebellar Purkinje cells (Obata, et a 1 ., 1967), inhibition 
of cerebellar Purkinje cells by basket cells (Crawford, Curtis, 
Voorhoeve and Wilson, 1963; Andersen, Eccles, L0yning and 
Voorhoeve, 1963) and inhibition of hippocampal pyramidal cells 
by basket cells (Andersen, et a 1., 1963) at which the inhibition
is probably mediated by GABA and not glycine. The strychnine 
antagonism of glycine has been suggested to be non-competitive 
(on spinal neurones) (Davidoff, et a 1., 1969) and competitive
(on cortical neurones) (Johnson, et a 1 . , 1970), but the
establishment of the nature of an antagonism from dose-response 
curves by microelectrophoresis is extremely difficult (Curtis, 
Duggan and Johnston, 1971c) „
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Amino acids tested upon spinal neurones by 
electrophoresis have been classified on the basis of their 
blockade by strychnine as "glycine-1ike" or "GABA-like"
(Curtis, et a 1 ., 1968a,b). This division of amino acids is 
supported by the bicuculline antagonism of "GABA-like" amino 
acids (Curtis, et a1., 1970a; Curtis, et al . , 1971b). The 
"glycine-like" amino acids include glycine, L-a-alanine,
DL-ß-aminoisobutyric acid, and taurine. Many compounds of 
diverse structure (Fig. 16) have strychnine-like action on 
spinal postsynaptic inhibition and reduce the depressant action 
of glycine when administered intravenously or 
electrophoretically, but all are less effective antagonists 
than strychnine (Curtis, et a1., 1968a).
Glycine synthesis
Glycine is a non-essential amino acid in mammals, and 
can be synthesised from glucose and a variety of other 
substrates in nervous tissue. Since serine and glycine are 
readily interconvertible in the CNS (Shank and Aprison, 1970), 
serine metabolism and its regulation are directly related to 
that of glycine. Serine is synthesised by two major 
pathways, the "phosphory1ated pathway" from 3-phosphoglycerate 
(Ichihara and Greenberg, 1957), and the "non-phosphory lated" 
pathway from D-glycerate (Sallach, 1956; Willis and Sallach, 
1962). Inhibition studies in the cerebral cortex have 
suggested that D-glycerate may be a more important precursor 
of glycine than 3-phosphoglycerate in nervous tissue (Uhr and 
Sneddon, 1971). Although no apparent correlation could be 
found between the rate of glycine formation and the glycine 
levels in those areas where glycine is probably an inhibitory 
transmitter (spinal cord, pons and medulla) (Shank and Aprison,
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1970), such a correlation appears to exist between the activity 
of D-glycerate dehydrogenase, but not 3-phosphoglycerate 
dehydrogenase, and glycine levels in the feline central 
nervous system (Uhr and Sneddon, 1972). This observation 
provides further evidence for D-glycerate as an important 
glycine precursor in nervous tissue, and suggests the 
"non-phosphorylated" pathway may be of more significance in 
glycine synthesis. The route from D-glycerate to glycine has 
not been established, but prob ably occurs through 
hydroxypyruvate and serine, and involves the enzymes 
hydroxypyruvate:a1 anine aminotransferase and L-serine 
5,10-hydroxymethy 1transferase (EC 2.1.2.1) (serine 
hydroxymethyl transferase) . The transaminase activity has 
been demonstrated in several tissues, but appears to be low 
in dog and beef brain (Walsh and Sallach, 1964), while serine 
hydroxymethy 1transferase has been shown in brain (Bridgers, 
1968; Alexander and Johnston, unpublished observations) and 
spinal cord (Alexander and Johnston, unpublished observations).
Glycine may also be synthesised by decarboxylation of 
hydroxypyruvate by means of hydroxypyruvate decarboxylase, 
which has been reported to exist in highest concentrations in 
the brain stem (Hendrick and Sallach, 1964). Glyoxylate may 
also be a precursor of glycine in the CNS for glycine:
2-oxog lutarate aminotransferase activity (EC 2.6.1.4) has been 
found in both the brain (Johnston and Vitali, 1969a) and 
spinal cord (Johnston and Vitali, 1969b; Johnston, Vitali and 
Alexander, 1970). Glycine is probably synthesised by a 
variety of other routes, but considerable work is necessary 
to further elucidate even major pathways.
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Glycine inactivation
The duration of transmitter action at spinal inhibitory 
synapses is very brief (Curtis and Eccles, 1959), and the 
termination of postsynaptic action could occur by diffusion 
(Eccles and Jaeger, 1958) and possibly by enzymic inactivation, 
but active transport from the synaptic cleft appears the most 
attractive method of transmitter inactivation. Central 
D-amino acid oxidase converts glycine to glyoxylate, and 
although limited activity is present in spinal grey matter, 
glycine is only a poor substrate, and this enzyme is probably 
of little importance in controlling the postsynaptic 
termination of glycine action (De Marchi and Johnston, 1969). 
Extracellular enzymes are unlikely to terminate transmitter 
action since specific enzyme inhibitors do not significantly 
influence spinal inhibitory transmission or the action of 
glycine (Curtis, et al., 1970b).
Glycine uptake has been demonstrated in slices and 
homogenates of cortex (Abadom and Schofield, 1962; Blasberg 
and Lajtha, 1965; Smith, 1967; Blasberg, 1968; Johnston and 
Iversen, 1971; Logan and Snyder, 1971) and spinal cord (Neal 
and Pickles, 1969; Neal, 1971; Johnston and Iversen, 1971; 
Logan and Snyder, 1971). Both high affinity (low Km) and 
low affinity (high Km) glycine uptake systems exist, and the 
high affinity system is found only in the pons, medulla and 
spinal cord (Johnston and Iversen, 1971), where glycine 
levels are highest and glycine is probably an inhibitory 
transmitter. Furthermore glycine uptake by grey matter of 
rabbit spinal cord is greater than that of white matter 
(Neal, 1971). This glycine transport system is active, 
specific, temperature sensitive, sodium dependent and shows
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saturation kinetics, (Neal, 1971; Johnston and Iversen, 1971). 
Subcellular distribution studies reveal that the accumulated 
glycine of both spinal cord and cortex is associated with a 
synaptosomal fraction, and that two distinct but overlapping 
populations of particles containing accumulated glycine and 
GABA exist (Iversen and Johnston, 1971). Light and electron 
microscopy have shown the accumulated glycine is localised 
over nerve endings (Hbkfelt and Ljungdahl, 1971; Matus and 
Dennison, 1971) and that the boutons contain "flattened" 
vesicles (Matus and Dennison, 1971), which are indicative of 
inhibitory synapses (Uchizono, 1965; Bodian, 1966 § 1967; Gray, 
1969) . The potent transport inhibitors p-hydroxymercuribenzoate 
and p-chloromercuripheny lsulphonate, (Curtis, et a 1 . , 1970b; 
Johnston and Iversen, 1971) potentiate the postsynaptic 
inhibitory action of glycine (Curtis, et al., 1970b), providing
further support for membrane transport as the mode of 
termination of transmitter action. Glycine uptake provides an 
effective recovery system for reconstituting presynaptic stores, 
terminating transmitter action and controlling intracellular 
concentration of this important amino acid.
Glycine release
Glycine release from central nervous tissue has been 
demonstrated in vitro (Hopkin and Neal, 1970) and in vivo 
(Jordan and Webster, 1971), but further work is necessary to 
investigate both the origin and the mechanism of the glycine 
release. The glycine efflux from slices of rat cord is 
multiphasic and spontaneous, but electrical stimulation or 
potassium depolarisation evokes an increased but non-specific 
efflux (Hopkin and Neal, 1970). Attempts to demonstrate a 
significant evoked release of glycine from slices of rat
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cerebral cortex (Mitchell» Neal and Srinivasan, 1969) or 
guinea-pig pyriform cortex (Mcllwain and Snyder, 1970) have 
been unsuccessful, but this failure to observe an increased 
efflux may be due to the small number of cortical synapses at 
which glycine acts as an inhibitory transmitter. While Katz, 
et al . , (1968) found a non-specific increased efflux from rat
brain slices of all amino acids studied on stimulation,
Mitchell, et al., (1969) found only GABA and glutamate release
were significantly increased. Efflux from slices appears to 
involve several different glycine pools and, as might be 
expected, is sensitive to both the slice size and the mode of 
electrical stimulation. Glycine release from the superfused 
hemisectioned toad cord has been reported to be increased by 
stimulation of the dorsal roots (Aprison, 1970), while the 
increased efflux of glycine from the cord of anaesthetised 
cats perfused with artificial cerebrospinal fluid could only 
be demonstrated in the presence of p-hydroxymercuribenzoate, 
a potent inhibitor of glycine uptake (Jordan and Webster, 1971). 
Clearly more work is needed to clarify glycine release and its 
underlying mechanisms.
Glycine satisfies all "criteria” for transmitter 
identification and is apparently the inhibitory transmitter at 
strychnine-sensitive spinal synapses - furthermore glycine 
may also be a transmitter in the pons and medulla. An 
increased knowledge of glycine metabolism and its controlling 
mechanisms would greatly assist understanding of how 
intracellular glycine levels are regulated.
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2. 4-AMINO- 3-HY PROXY ISO XA.Z OLE , AN ISOXAZQLE ANALOGUE OF GLYCINE
Mushrooms, particularly those of the species Amanita, 
have long been known to be poisonous, and extracts of Amanita 
muscaria have been employed as a fly agaric and as a 
hallucinogen. In fact ingestion of this mushroom produces 
psychomimetic effects afer 15-20 minutes (Farnsworth, 1968).
Substances isolated or detected in A. muscaria include 
choline, acetylcholine, muscarine, muscaridine, muscimol, 
ibotenic acid and muscazone. The symptoms of A. muscaria 
intoxication are complex, and resemble those of a drug 
possessing both central and peripheral effects (Wieland, 1962) . 
Muscarine has a strong parasympathetic peripheral action, but 
cannot be the poisonous principle for it occurs at a 
concentration of only .0002% in the fresh mushroom (Wieland, 
1962). However, ibotenic acid is found at concentrations of 
.03-.1% (Wieland, 1962; Good, MUller and Eugster, 1965), while 
muscimol easily forms from ibotenic acid by decarboxylation, 
and both these compounds are centrally active (Waser, 1967; 
Scotti, Lipparni and Longo, 1969). Muscimol (pyroibotenic 
acid, pantherine, agarin or 3-toxin) and ibotenic acid 
(pramuscimol or a-toxin) have been isolated from A. muscaria,
A. patherine and A. strobiliformis (Onda, Fukushima and 
Akagawa, 1964; Takemoto, Yokobe and Nakajima, 1964; Takemoto, 
Nakajima and Sokuma, 1964; MUller and Eugster, 1965; Good, 
et a 1 . , 1965; Bowden and Drysdale, 1965; Bowden, Drysdale and 
Mogey* 1965; Eugster, MUller and Good, 1965), and both are 
simple isoxazoles (Fig. 17). Both produce intoxication and 
hallucinations (Waser, 1967), and are lethal (muscimol 
LD^-q 4.5 mg/kg and ibotenic acid L D ^  42 mg/kg in the rat), 
(Theobald, Buch, Kunz, Krupp, Stenger and Heimann, 1968).
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Fig. 17
Structures of muscimol, ibotenate, GABA and glutamate.
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However, psychological tests reveal muscimol is at least five 
times more active than ibotenic acid (Theobald, et al . , 19 6 8).
Both muscimol and ibotenic acid have direct effects on 
central neurones, and depress and excite the firing of spinal 
interneurones respectively (Johnston, et al . , 1968). They
may act as conformationally restricted analogues of GABA and 
glutamate (Fig. 17) (Johnston, et al., 1968), which have
powerful depressant and excitatory actions on neurones, and 
probably function as inhibitory and excitatory transmitters 
at certain synapses in the mammalian central nervous system 
(Curtis and Johnston, 1970). These isoxazoles have actions 
equipotent to or more potent than those of the natural amino 
acids, and this potency may reflect their ineffective removal 
from the postsynaptic receptor by the specific membrane 
transport systems (Johnston, 1971; Balcar and Johnston, 1972). 
Furthermore the depressant action of muscimol is blocked by 
the convulsant alkaloid bicuculline (Curtis, et a1., 1970),
which appears to be a specific antagonist of "GABA-like" 
amino acids (Curtis, et al . , 1968b). Recent studies on 
neurones of the snail, Helix aspersa, support the suggestion 
that the two isoxazoles function as analogues of GABA and 
glutamate, and act at the same receptors (Walker, Woodruff 
and Kerkut, 1971).
Muscimol and ibotenic acid are both 3-hydroxyisoxazoles 
and exist in the hydroxy (enol) rather than the isoxazolone 
form (Bravo, Gaudiano, Quilico and Ricca, 1961) - the addition 
of an amino group almost certainly makes them zwitterionic, 
with amino acid-like properties. The planar nature of the 
aromatic isoxazole ring probably holds the substitutents 
important in receptor-agonist interactions in a conformation
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such that the molecule acts as a conformationally restricted 
analogue, which might represent an important in vivo transmitter 
conformation active at the postsynaptic receptor. Extended 
conformations of GABA appear to be important for the synaptic 
action (Beart, et al., 1971) and molecular orbital 
calculations (Kier and Truitt, 1970) support the idea 
(Johnston, et al . , 1968) that muscimol can function as a 
conformationally restricted GABA analogue.
In view of this particular property of the isoxazole 
moiety, an obvious extension of these structure-activity 
correlations is to predict that the corresponding isoxazole 
analogues of glycine and aspartate, amino acids which are also 
transmitter candidates in the mammalian central nervous system 
(Curtis and Johnston, 1970), might also be
neuropharmacologically active. The analogue of aspartate 
cannot exist, but the glycine analogue is
4-amino-3-hydroxyisoxazole (Fig. 18). Interestingly this 
compound is also an analogue of cycloserine 
(4-amino-3-hydroxyisoxazolidine) (Fig. 18), a drug whose 
clinical use in tuberculosis has been limited by its side 
effects on the central nervous system.
Cycloserine has been widely used in the treatment of 
tuberculosis since its isolation and synthesis (Harned, Hidy 
and La Baw, 1955; Kuehl, et al., 1955; Hidy, et a 1., 1955;
Stammer, Wilson, Holly and Folkers, 1955), and its mode of 
action is considered to be inhibition of bacterial cell wall 
synthesis (Curci, 1970). Unfortunately a relatively high 
proportion of all patients suffer from neuropsychiatric side 
effects (Pasargiki1ian and Biondi, 1970), which include 
convulsions, hallucinations and behavioural disorders (Leston,
+GLYCINE
+
4-AMINO-3-HYDROXYISOXAZOLE
+
CYCLOSERINE
Fig. 18
Structures of glycine, 4-amino-3-hydroxyisoxazole
and cycloserine.
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Rey, Gonzalez Montaner^ Grondona and Zavalla, 1970).
Further cycloserine accumulates in the cortex, medulla 
oblongata, cerebellum and cerebrospinal fluid of cynocephalic 
(dog-faced) monkeys after administration (Coletsos, 1970). 
Cycloserine effects the electroencephalogram (Schmelev, 1970; 
Vassileva, 1969; Vassileva and Stoneva, 1969), depresses the 
firing of neurones (Curtis, unpublished results) and inhibits 
the important GABA-metabolising enzymes glutamate 
decarboxylase and GABA aminotransferase (Sashchenko, Severin 
and Khomutov, 1968; Scotto, Monaco, Scardi and Bonavita, 1963; 
Dann and Carter, 1964; Severin, Sashchenko, Kovaleva and 
Khomutov, 1968). This biochemical interference by cycloserine 
is almost certainly due to its ability to bind strongly to 
pyridoxal phosphate and hence inhibit enzymic catalysis.
Such a broad spectrum of effects may result in a disturbance 
of central nervous system function, but some central effects 
of cycloserine might well result from its conversion to the 
corresponding isoxazole, 4-amino-3-hydroxyisoxazole. This 
dehydrogenation (oxidation) could be catalysed by a 
non-specific dehydrogenase, or by a specific enzyme induced 
by prolonged treatment with the drug, or might occur 
spontaneously.
To investigate whether 4-amino-3-hydroxyisoxazole can act 
as conformationally restricted glycine analogue, and whether 
it is linked to the central effects of cycloserine, a 
synthesis of the molecule was undertaken. Very few simple 
3-hydroxyisoxazoles apart from muscimol, ibotenic acid and 
related compounds are known - most others are stabilised by 
aryl substituents in the 4 and 5 positions. The simplest 
approach to the synthesis is to attempt the dehydrogenation
62
(i.e. oxidation) of cycloserine. Such conversions have been 
achieved (for example, Jorlander, 1916), but always involve 
or proceed via an elimination from an isoxazoline with a good 
leaving group in the 4 or 5 position. Possibly the conversion 
of cycloserine to the corresponding isoxazole under conditions 
employing a dehydrogenating agent might proceed because of the 
gain in resonance energy accompanying aromatisation - however 
such reactions generally require high temperatures and it is 
doubtful whether cycloserine could withstand such conditions.
Total syntheses of 3-hydroxyisoxazoles have always 
involved cyclization of an aliphatic precursor to the isoxazole 
and subsequent conversion to the required product. A common 
approach to introduce the 3-hydroxy moiety has been to prepare 
a 3-ha 1oisoxazo1e from the appropriate $-nitroketone (Fusco 
and Rossi, 1962), and to convert this to the required species 
via a 3-alkoxyisoxazole (for example Fig. 19; Gagneux,
Hafliger, Eugster and Good, 1965). The other major route to 
3-hydroxyisoxazoles has been by the cyclisation of the 
appropriately activated hydroxamic acid - either a 3,3-dialkoxy 
(Gagneux, et a 1 . , 1965; Fig. 19), 3-ha1oethy 1enic (Nakamura, 
1971) or acetylenic hydroxamic acid (Kishida, Hiraoka, Ide, 
Terada, Nakamura, 1966). The synthesis of 4-amino-3- 
hydroxyisoxazole was approached by the following routes:
(1) the dehydrogenation of cycloserine,
(2) generating the appropriate 3,3-dialkoxy hydroxamic acid, 
and
(3) preparing a 3-substituted ethylenic hydroxamic acid.
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Syntheses of 3-hydroxyisoxazoles
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RESULTS
None of the projected synthetic approaches have so far 
led to a useful preparation of pure 4 - amino-3-hydroxyisoxazo1e
Scheme 1
Cycloserine (1) could not be oxidised to 
4-amino-3-hydroxyisoxazo1e (2) by any of the reagents employed 
Activated manganese dioxide in inert solvents has been widely 
used to achieve selective oxidations and hence 
dehydrogenations of dihydro compounds to their corresponding 
heteroaromatics (Pratt and McGovern, 1964; Barton, Kenner and 
Shepperd, 1966; Meth-Cohn and Suschitzky, 1969), while 
mercuric acetate has been employed for the introduction of 
double bonds in many hererocyclic molecules (Lee, 1969). 
Alkaline potassium ferricyanide has been used as an oxidising 
agent because of its ability to function as a complex 
electron abstracting ion, and N-bromosuccinimide has been 
employed in a similar manner, and owes this activity to its 
ability to brominate molecules, which can undergo subsequent 
dehydrobromination. Cycloserine was not dehydrogenated by 
any of these reagents, and was generally unaffected by the 
conditions employed.
Scheme 2
An attempt to synthesise 4-amino-3-hydroxyisoxazole (2) 
was made by a procedure similar to that used by Gagneux, 
et al., (1965) for the synthesis of muscimol, which involved
preparation of a ß,3-dialkoxy hydroxamic acid. Glycine ethyl 
ester (3) underwent formylation to N-formyl glycine ethyl 
ester (4) very readily, and was converted to sodium
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norpenaldate (5) in almost quantitative yield. This sodium 
enolate when treated with ethanolic hydrogen chloride formed
3.3- diethoxyalanine ethyl ester (6) in moderate yields.
3.3- Dialkoxy esters (Gagneux, et al., 1965, Goth, Gagneux,
Eugster and Schmid, 1967) and amino acid esters (Cunningham, 
Newbold, Spring and Stark, 1949) are usually easily converted 
to their corresponding hydroxamic acids, but all attempts to 
convert 3,3-diethoxyalanine ethyl ester to its hydroxamic acid 
(7) produced only a trace of product, whose infrared and mass 
spectra, and positive test with aqueous ferric chloride 
solution were consistent with the desired hydroxamic acid.
This failure to obtain the hydroxamic acid in useful amounts 
may be due to the unsuitability of 3,3-diethoxyalanine ethyl 
ester as an intermediate, for it has been suggested to undergo 
extensive diketopiperazine formation (Brown, 1949).
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Scheme 5
Nakamura (1971) has synthesised muscimol by an elegant route 
involving the cyclisation of a 3-substituted hydroxamic acid, 
and the synthes is of 4-amino - 3-hydroxyisoxazo1e (2) was 
approached through a similar intermediate - a-phenylacetamido-
3- ethy 1thiomethy1eneacry1ohydroxamic acid (13). The synthesis 
of this intermediate was initiated from hippuric acid (8) 
which was easily cyclised to 2-pheny1-4-ethoxymethy 1eneoxazo1- 
5-one (9) by an "orthoformate" synthesis (Cornforth, 1949). 
Since the reduced activity of the side chain of
4 - a 1ky1thiomethy 1eneoxazo1-5 - ones, renders them more 
susceptible to ring opening than the corresponding
4- alkoxymethyleneoxazol~5-ones, this compound was converted to 
2-phenyl-4-ethylthiomethyleneoxazol-5-one (10), which was
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easily hydrolysed with aqueous potassium hydroxide to 
a-phenylacetamido-3-ethylthiomethyleneacrylic acid (11) in a 
convenient yield.
Conversion of this acid to the activated cyanomethy 1ene 
ester (12) (Stewart, 1970) gave a suitable ester for the 
preparation of the 3-substituted ethylenic hydroxamic acid 
(13). This ester was allowed to stand with excess 
hydroxylamine in dimethy1formamide at room temperature for 
several days - initially the mixture was bright yellow in 
colour, with the evolution of pungent vapour (ethane 
thio1/triethy 1 amine), but became colourless on standing, and 
the evolution of gas ceased. The chromatographic procedure 
of Frater-Schröder, Good and Eugster (1969) was adopted to 
isolate the hydroxamic acid (13), which was eluted from the 
anion exchange resin with approximately 2 M aqueous acetic 
acid and identified by its characteristic purp 1e-c1aret 
colour with aqueous ferric chloride solution. When the 
acetic acid was removed in a vacuum (approximately 50°/water 
pump pressure) the product isolated gave a negative test 
with aqueous ferric chloride and appeared not to be the 
hydroxamic acid, but the cyclised product formed by internal 
nucleophilic displacement of ethane thiol. Although a 
satisfactory analysis was never obtained for this compound, 
the reaction was repeated many times and the infrared, n.m.r. 
and mass spectra were always consistent with the product 
being 4-benzoylamino-3-hydroxyisoxazo1e (14).
An excess of concentrated sulphuric acid was initially 
employed to hydrolyse the benzamido group (vigorous 
conditions such as these are generally required for amide 
hydrolysis, and isoxazoles are usually stable to acid) and
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produced a pink solution, which darkened with increasing 
reaction time. Subsequent cooling precipitated crystals of 
benzoic acid, but the mother liquor when chromatographed on 
Dowex 50 W H to isolate zwitterionic compounds gave glycine 
as the sole product in approximately 20% yield. When the 
hydrolysis was carefully examined by TLC of small scale 
reactions and the products located by ninhydrin, first a 
yellow spot formed, then on longer heating a second purple 
spot of higher Rf, corresponding to glycine, became visible, 
and on further heating two more spots of lower Rf than the 
initial spot appeared - the initial yellow spot on standing 
a few hours darkened to a pink-brown colour. Hence the 
initial product formed by the hydrolysis of 4-benzoylamino- 
3-hydroxyisoxazole was sensitive to both acid and heat, and 
was probably undergoing hydrolysis of the isoxazole ring with 
increasing reaction time.
The best conditions for amide hydrolysis appeared to be 
a 10 minute reflux with 10 moles of 2M hydrochloric acid 
(diluted 1:1 with 2M aqueous acetic acid). Preparative TLC 
on cellulose allowed the starting material to be separated, 
but the required product (2) could not be separated from 
glycine by this chromatography procedure. However, paper 
column chromatography employing n-butanol/acetic acid/water 
(4/1/1) as the eluting solvent gave a clear separation - 
product Rf=0.27 and glycine Rf=0.34. Those fractions 
containing the product of low Rf (2) were identified by their 
colour with ninhydrin and their purity checked by TLC on 
cellulose, combined and carefully evaporated to dryness in a 
vacuum at room temperature. Even with subsequent preparative 
TLC on cellulose the last traces of glycine could not be
6 7
removed - the compound seemed to undergo at least partial 
decomposition to glycine even under the relatively mild 
isolation procedures used.
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DISCUSSION
The desired isoxazole analogue of glycine,
4-amino-3-hydroxyisoxazole has been prepared and identified 
by TLC, but isolation of sufficient amounts for pharmacological 
testing and investigation of a possible link to central 
effects of cycloserine will require a very mild hydrolysis 
procedure in the final step of scheme 3, and a more efficient 
chromatographic separation, particularly in view of its 
apparent acid lability. An obvious modification of scheme 3 
is to use a more labile protecting group (for example 
2,4-dinitrobenzoy 1) for the amino function, which would enable 
much milder conditions to be used in the final hydrolysis step.
The attempted synthesis of the 8-substituted ethylenic 
hydroxamic acid (13) directly from 2-pheny1-4-ethy1thiomethy 1- 
eneoxazo1-5 - one (10) using hydroxy1 amine in methanol did not 
result in the desired hydroxamic acid, but gave instead the 
corresponding methyl ester - strangely the isoxazolone must 
be more sensitive to ring opening by methanol than the 
stronger nucleophile, hydroxylamine. This failure to prepare 
the hydroxamic acid directly from 2-pheny1-4-ethy 1- 
thiomethyleneisoxazol-5-one meant that the isoxazolone had to 
be opened first to the carboxylic acid (11), and the 
hydroxamic acid (13) subsequently generated from it by one 
of the standard procedures. Diazomethane quantitatively 
methylated the carboxylic acid to a-phenylacetamido-8- 
ethylthiomethyleneacry lie acid methyl ester (surprisingly the 
methylation would only occur if the starting acid was 
analytically pure), but this ester could not be converted to 
the corresponding hydroxamic acid. Furthermore, attempts to 
prepare the acid chloride and synthesise the hydroxamic acid
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by this method were also unsuccessful., Only activation of the 
carbonyl group by the cyanomethylene moiety allowed the 
hydroxamic acid to be prepared. This failure of hydroxy lamine 
to react at the carbonyl group may be due to the fact that the 
molecule is both an a,8-unsaturated carbonyl compound and an 
enamine, and hence all the positive character of the carbon of 
the carbonyl group essential for nucleophilic attack by 
hydroxylamine is delocalised, making the carbonyl group 
unreactive. The electron withdrawing effect of the cyano 
group must increase the contribution of the canonical form 
with the positive charge on the carbon of the carbonyl group 
to such an extent that nucleophilic attack can now occur.
Once the a-pheny1acetamido-3-ethy 1thiomethy 1eneaery 1o- 
hydroxamic acid (13) was formed it apparently underwent 
cyclisation very readily to 4-benzoylamino-3-hydroxyisoxazole 
(14). Although never isolated, it could be eluted from an 
anion exchange column and identified by its positive ferric 
chloride test. Clearly the 3-ethy1thiomethylene hydroxamic 
acid was a more activated species than the 3,3-dialkoxy 
hydroxamic acid for these intermediates needed more vigorous 
conditions to undergo cyclisation, for example treatment with 
absolute acetic acid saturated with dry hydrogen chloride at 
20° for 16 hours (Gagneux, et a 1., 1965) or distillation at 
175° and 0.01mm pressure (Goth, et al ., 1967), while only
aqueous acetic acid at approximately 50° and water pump 
pressure was necessary to induce cyclisation to 
4-benzoylamino-3-hydroxyisoxazole.
Hydrolysis of 4-benzoylamino-3-hydroxyisoxazole (14) gave 
a product which behaved in a very similar manner to previously 
described simple 3-hydroxyisoxazoles. This compound when
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sprayed with ninhydrin gave initially a yellow colour, but 
darkened on standing to pink-brown. Both muscimol and 
ibotenic acid have been reported to undergo such changes - 
muscimol from orange to violet (or brown to red-violet) and 
ibotenic acid from gold to violet (Onda, et a 1 . , 1964; Good,
et al., 1965). Furthermore, muscimol when heated in a
sealed tube with 6M hydrochloric acid lost its biological 
activity and three amino acids were identified by TLC (Onda, 
et al., 1964) - this observation was the basis of the 
suggestion that muscimol was a peptide, but muscimol is 
obviously acid labile and the amino acids were formed by the 
hydrolysis of the isoxazole ring. Clearly the initial product 
formed by hydrolysis is behaving in an identical manner to 
muscimol, and is probably the desired product 4-amino-3- 
hydroxyisoxazole (2), but is apparently more acid labile than 
muscimol. A possible explanation of the acid breakdown of 
4-amino-3-hydroxyisoxazole is suggested in scheme 4.
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1. GENERAL
Analyses
Dr. J.E. Fildes and her staff of the Department of 
Medical Chemistry, AoN.U. carried out the elemental analyses.
Melting points
Melting points were determined on a Yanagimoto micro 
melting point apparatus and are uncorrected.
Spectra
Infrared spectra were recorded using a Perkin-Elmer 
model 21 or a Unicam SP 200 spectrophotometer, and unless 
otherwise stated were recorded as potassium bromide disks.
Mr. S. Brown of the Department of Medical Chemistry, 
A.N.U. recorded the n.m.r. spectra at 60 Mhz. on a 
Perkin-Elmer RIO spectrometer. All chemical shifts were 
measured on the 6-scale relative to sodium
trimethy Isi ly Ipropanesulphonate in D^O, and tetramethyIsilane 
in organic solvents.
Mass spectra were measured at 70 eV using a direct inlet 
system on an A.E.I. MS902 (Research School of Chemistry, 
A.N.U.) or a Hitachi Perkin-Elmer RMU 6D spectrometer 
(Division of Applied Chemistry, CSIRO, Melbourne) by 
Dr. J.K. Macleod and Dr. J.A. Wunderlich respectively.
pK Measurements
Mr. D. Light and Mr, I.J. Hawkins of the Department of 
Medical Chemistry, A.N.U. made the pK measurements by 
titration in aqueous solution at 20°.
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Amino acid analyses
Mr. L.B. James determined the amino acid analyses in the 
Department of Biochemistry, The Institute of Advanced Studies, 
on a modified Technicon Auto Analyser (James, 1972) using the 
two-buffer system of Spackman, Stein and Moore (1968).
Chromatography
Ion exchange resins were always suspended in water, 
allowed to settle, the "fines" decanted, and the resin 
recycled by washing thoroughly with approximately 2M 
sodium hydroxide, water and 2M hydrochloric acid before 
column preparation. Thin layer chromatography (TLC) on 
cellulose (avicel) plates (20cm X 20cm X 0.025cm) was carried 
out using an ascending solvent front. TLC on silica gel was 
carried out on microscope slides coated with the adsorbent by 
dipping the slides in a chloroform suspension of silica gel G 
and air drying. For preparative TLC, plates (20cm X 20cm X 
0.2cm) were prepared from 17.5 g of silica gel and
17.5 g of silica gel G in 89 ml of water - the ascending 
technique was again used and the compounds located under an 
ultraviolet lamp. When cellulose was employed as the adsorbent 
for preparative TLC (20 g of avicel in 65 ml of water, plate 
thickness 0.15-0.20cm) compounds were located with ninhydrin.
Paper column chromatography was carried out on a Chromax
LKB pressurised paper chromatography system (4cm X 36cm column)
2at a pressure of 0.3-0.4 kg/cm (maintained with a pressure 
ballast head) in conjunction with a Towers fraction collector, 
taking 10 ml fractions.
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Intravenous injections
Mice (50-60g, either sex) were restrained in a suitable 
plastic centrifuge tube (with an air hole cut at the top), and 
their tail veins dilated by inverting the centrifuge tube in 
approximately 1" of warm water. The tube was removed from 
the water, the mouse held in position by compressing the open 
end of the centrifuge tube with the second finger, the tail 
vein constricted between the forefinger and the thumb, and 
the injection made into one of the tail veins with a sterile 
Terumo 25 gauge needle fitted to Stylex lee tuberculin 
syringe. Compounds to be injected were made up to the 
required concentrations (as the hydrochlorides where necessary) 
and injected in a volume never exceeding 0.4 mis.
Microelectrophoresis
Experiments were performed on cats anaesthetised with 
pentobarbitone sodium. Extracellular action potentials were 
recorded from the centre barrel of seven barrel micropipettes 
and the compounds to be tested were administered from the 
outer barrels of the micropipettes. The solutions used were 
as follows: GABA, 0.5 M, adjusted to pH 3 with hydrochloric
acid; glycine, 0.5 M pH 3, HCl; DL-homocysteate, 0.2 M, pH 
7.5, NaOH; bicuculline hydrochloride, 5 mM in 165 mM NaCl, 
pH 3, HC1; strychnine hydrochloride, 2 mM in 165 mM_ NaCl, pH 
3, HC1; 4-aminotetrolic acid, 0.5 M, pH 3, HC1;
4-morpholinotetrolic acid, 0.5 M, pH 3, HC1;
4-piperazinotetrolic acid, 0.5 M, pH 3, HC1;
4-piperidinotetrolic acid, 0.5 M, pH 3, HC1;
4-pyrrolidinotetrolic acid, 0.5 M, pH 3, HC1; bicuculline
diol, 20 mM in 165 mM NaCI, pH 3, HC1; aminophthalidylmethane 
hydrochloride, 0,1 M, pH 4, HC 1; sal solinol hydrochloride,
0.1 M, pH 3, HC1.
Scintillators
The Triton scintillator contained 0.4% 2,5-diphenyloxazole
in a 2:1 mixture of toluene and Triton X-100. The dioxan
scintillators employed were those of Bray (1960), and one
containing 0.5% 2,5-diphenyloxazole and 10% naphthalene in
dioxan. Counting efficiencies of these scintillators under
the conditions normally employed (1 ml of aqueous solution in
10 ml of scintillator) in a Beckman LS100 counter were as
3 14follows: Triton scintillator; H 5%, C 80%; Dioxan
3 14scintillators; H 35%, C 80%.
Radiochemicals
3L-Glutamic acid- H(G), specific activity 1.46 C/mmole,
3and GABA-2,3- H, specific activity 2 C/mmole were obtained
14from New England Nuclear, Boston. GABA-1- C, 15 mC/mmole, 
was obtained form Calatomic, Los Angeles.
Drugs and Chemicals
GABA analogues. The following were gifts: cis-3~
aminocyclohexanecarboxylic acid (Dr. D.I.B. Kerr, Adelaide), 
trans-3-cyclohexanecarboxy1ic acid (Dr. F. Hewgill,
Perth), 2-amino,2-aminomethy 1cyc1ohexanecarboxylie acid,
cis- and trans - 2 - ami nocyc1ohexanecarboxy1ic acid
(Dr. W.L.F. Armarego, Canberra), 2-oxo-GABA hydrochloride
(Prof. L. Fowden, London), N-formyl, N-acetyl and N-lauryl-
GABA (Prof. E. Roberts, Duarte), homohypotaurine
(Dr. Jo 1les-Bergeret, Orsay), 4-hydroxypyrrolidin-2-one
(Prof. C.H. Eugster, Zurich), 2-guanidinoethanethiosulphonic
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acid (Dr. D .L . Klayman, Washington). Dr. J.C. Watkins 
prepared the following compounds in Canberra: 
pyrrolidin-2-one, 3 - aminopropane boronic acid, and GABA
methyl ester,. The following compounds were synthesised by 
Dr. D. Butler, Canberra: y-butyrobetaine, 3-aminopropane
sulphonic acid, 4-aminovaleric acid and formimidoylglycine. 
Dr. G.A.R. Johnston prepared the following compounds by 
published procedures: 2-ureido-GABA,"4-aminoxy-GABA",
ureidooxyacet ic acid, oxaluric acid and 2-guanidino-2 - 
phenylacetic acid. 2-Bromo, 2-methyl and 2-hydroxy-GABA were 
prepared by Mr. B. Twitchin.
The following were purchased: 2-aminoheptane sulphate,
ethyl piperidine-4-carboxylate, piperidine-4-carboxylic acid 
and piperidine-1-carboxamide (Fluka); p-aminomethy lbenzoic 
acid, cis- and trans - 4-aminomethy Icyc1ohexanecarboxy1ic acid 
(cis- and transexamic acid) (KABI); glycyl-GABA,
D-glucosaminic acid and isonicotinic acid (Nutritional 
Biochemicals); N-methy1-GABA and GABA amide (Lederle Labs);
2-aminoethane sulphonic acid and L-azetidine-2-carboxylic 
acid (Calbiochem.); 2-aminoethanethiosulphonic acid (Eastman 
Organic); ureidoacetic acid (K and K); N-(2-imidazoy1iny1)- 
glycine (Aldrich); 3-pyridineacetic acid (Baker).
Drugs. The following were gifts: amiloride
(Dr. A.W. Cuthbert, Cambridge); 5-azaindole (Prof. A. Albert, 
Canberra); reserpine hydrochloride (Riker Labs); bicucine, 
adlumine and corlumine (Dr. R.H.F. Manske, Waterloo); 
bulbocapnine hydrochloride (Merck, Sharp and Dohme); S 1976,
S 2017, S 1574, S 1694 and S 2428 (Dr. Poignant, Suresnes) 
were all phenothiazine analogues. Dr. G.A.R. Johnston 
prepared bicuculline diol by a literature procedure.
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The following were obtained from commercial sources:
bicuculline, hydrastine, narcotine and laudanosine (Fluka and
Pierce); antimycin A, valinomycin, chloroamphenico1
(Calbiochem); mitomycin C, gramicidin D, oligomycin (15%A and
85%B) , puromycin, strophanthidin, cy c 1 ohexi mide , juglone, N^1, 
20 -dibutyryl-3',51-cyclic AMP and monosodium 3',5’-cyclic AMP 
(Sigma Chem. Corp0); 1-adamantanamine and hemicholinium 3 
dibromide (Aldrich); protoveratrine A and B (Mann); cocaine 
(Chinin fabrik Braunschweig Buchler and Co„)> coniine (Koch 
Light) .
SYNTHESES2 .
(A) CQNFQRMATIQNALLY RESTRICTED GABA ANALOGUES 
4- Aminotetrolic acid
Concentrated ammonia (45 ml, density ca„ 0.91) was added 
to a mixture of 4-chlorotetrolic acid (630 mg, b.p.
88-91/7 mm) and ice (ca. 10 g). The solution was allowed 
to stand at O' for 1 hour, at room temperature for 1 hour, 
and at 4° for 3 days. The resulting yellow solution was 
taken to dryness in a vacuum, dissolved in the minimum 
quantity of water and chromatographed on a column (3cm X 10cm) 
of Dowex 50W(H ) ion-exchange resin (200-400 mesh). Elution 
with water (300 ml) removed unreacted 4-chlorotetrolic acid. 
The product was then eluted with aqueous pyridine (1 M,
200 ml) (Watkins, 1962), the eluant evaporated to dryness in 
a vacuum, the residue dissolved in water and again evaporated 
to dryness to remove the last traces of pyridine. 
Recrystallization from ethanol/water after deco1 ourisation 
with charcoal gave colourless crystals (135 mg, 25% yield),
m ,p. abo ve 3 00° (Found: C, 48.5; H, 5.1; N, 14.1. Calc .
for C4H5N02: c, 48.6; H, 5.1; N, 14.1%) . v 3 110 , 2990,
2640, 2500, 2240 (C=C), 2115 (N+H), 1635 (CO “), 1350 ( c o / )
805 and 775 - 1cm ; +mass spectrum m/e 99 (M , 6%) /—\r—< r-Hv—J00C
82 (M-OH, 5) , 70 (M-HN=CH2, 7) and 54 (98-C02, 100%, base
peak). pK values: 1.80±0.02, 8.34±0.02. pK values for 
GABA measured under similar conditions (King, 1954): 4.04, 
10.71.
The following methods were found to be unsuitable for 
the preparation of 4-aminotetrolic acid by amination of 
4-chlorotetrolic acid. (1) Decomposition of the hexamine 
adduct under acidic conditions (Hillman and Hillman, 1948).
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(2) Stirring 4-ch1orotetrolic acid with concentrated aqueous 
ammonia at room temperature for 2 days. (3) Employing 
ammonium carbonate and concentrated aqueous ammonia as the 
aminating agent. (4) A small scale amination with liquid 
ammonia gave traces of a product having the mass spectrum of 
4-aminotetrolic acid, but attempts to scale up this procedure 
resulted in the formation of intensely coloured products. 
4-Morpholinotetrolic acid
This was prepared from aqueous morpholine (1.2 g in 10 ml 
water) and a mixture of 4-chlorotetrolic acid (460 mg) and 
ice (ca. 10 g). After 2 hours at 0° and 20 hours at room 
temperature, the mixture was worked up as before and 
recrystallized from water/ethano1/ether to yield colourless 
crystals (280 mg, 43%), m.p. above 300° (Found: C, 56.7;
H, 6.6; N, 8.3. Calc, for C . H N O  ■ C, 56.8; H, 6.6; N,o i l  O
8.3%). v , 2940, 2850, 2150 (CeC and N+H), 1615 (CO ~) andmax z
1340cm 1 (C02 n.m.r. spectrum (D^O) 6 4.19 (2H, singlet), 
4.01 (4H, triplet J=5 Hz) and 3.45 (4H, triplet J=5 Hz); 
mass spectrum m/e 169 (M+ , 2%), 148 (7), 125 (M-CO^, 39),
124 (18), 95 (8), 94 (125-OCH3> 34), 86 (24), 82 (6), 80 (12), 
68 (94-C2H2, 29), 67 (33), 66 (15), 56 (16), 55 (90), 54 (10), 
44 (100%, base peak). pK values: 1.79±0.02, 5.57±0.05.
4-Piperazinotetrolic acid
This was prepared from aqueous piperazine (2.41 g in
10 ml water) and 4-ch1 orotetro1ic acid (920 mg) in ice, as
described above (1 hour at 0°, 22 hours at room temperature),
as colourless crystals (610 mg, 46%) from water/ethano1/ether,
melting partially above 220° (Found: C, 57.1; H, 6.9; N,
16.6. Calc, for CgH 12N202: C, 57.1; H, 7.2; N, 16.7%).
v 3410 (N-H), 2950, 2830 , 2725, 2470 , 2210 (C = C) , 1645 max
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CC0  ^ ), 1360 and 132 5 cm l; n.m.r. (D?0) 6 3.54 (2H, singlet), 
3.30 (4H, multiplet) and 2.93 (4H, multiplet); mass spectrum
m/ e 168 (M+ , 24%), 140 (5), 126 (M-CH2N=CH2, 28), 124 (M-CO 2,
54) , 109 (124-CH , 15), 96 (9) , 95 (8), 94 (15), 85 (12), 83
(19) , 82 (124-CH?N =CH2, 100% base peak), 56 (39) . pK
values 2.78±0.04, 9.28±0.05 (only two could be measured). 
4-Piperidinotetrolic acid
This was prepared from aqueous piperidine (2.63 g in 
10 ml water) and 4-chlorotetrolic acid (880 mg) as above 
(2 hours at 0°, 20 hours at room temperature). 
Recrystallization from methanol/ether gave colourless 
crystals (650 mg, 53%), m.p. above 300° (Found: C, 64.9;
H, 7. 8; N, 8.6. Calc,. for CgH 13N02: C, 64 .7; H , 7.8; N, 8.4%)
V max 2960, 2300 (CEC and N+H), 1600 (CO ") and 1355 cm'1
(co2-); n.m.r. Cd 2o ) 6 4.08 (2H, singlet), 3.35 (4H,
multiplet) and 1.70 (6H, multiplet); mass spectrum m/e 167 
(M+, 2%), 166 (4), 123 (M-C02, 40), 122 (100%, base peak),
108 (123-CH3, 5), 94 (122 - C2H , 15), 84 (12), 83 (16),
82 (108_C2H2, 17), 80 (11), 68 (10), 67 (14), 55 (23),
54 (11), 44 (67). pK values: 1.78±0.04, 8.03±0.03.
4-Pyrrolidinotetrolic acid
When aqueous pyrrolidine (1.04 g in 10 ml water) was 
added to a mixture of 4-chlorotetrolic acid (500 mg) and ice 
(ca. 10 g) there was an immediate reaction with the evolution 
of white fumes. Afer 15 minutes the resulting pale yellow 
solution was worked up in the usual way. Recrystallization 
from methanol/ether gave colourless crystals (325 mg, 50%), 
m.p. above 300° (Found: C, 62.8; H, 7.1; N, 9.1. Calc,
for C „H NO : C, 62.7; H, 7.2; N, 9.1%). If the reaction
mixture was allowed to stand a further 15 minutes at 0°, a
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deep yellow solution was produced from which the desired 
product could be isolated in only 20% yield. vmax 2930,
2230 (C=C), 2060 (N + H) , 1605 (CO/) and 1325 cm"1 (C02); mass 
spectrum m/e 153 (M+ , 3%), 152 (5), 109 (M-CO , 47), 108 
(152-C02, 100%, base peak), 94 (109-CH 4), 81
(109-C2H4 , 20), 80 (10), 70 (94-C,,H9, 14), 68 (13), 66 (10), 
55 (8), 44 (57); n.m.r. (D70) 6 4.14 (2H, singlet), 3.42 
(4H, triplet J = 7 Hz) and 2.07 (4H, quintet J=4 Hz). pK 
values: 1.76±0.05, 8,25±0.02.
Trans - 4-aminocrotonic acid
4-Amino-3-hydroxybutyric acid was dehydrated to 
trans-4-aminocrotonic acid by heating with concentrated 
sulphuric acid at 130° for 1 hour (Musashi, 1954). 
Recrystallization from aqueous ethanol (or water/ethanol/ 
ether) gave colourless crystals, m.p. 165.5- 168r' decomp.
(lit. m.p. 164° decomp.; Pollock and Stevens, 1965a)
(Found: C, 47.7; H, 6,9; N, 13.5 . Calc, for C4H7N02:
C , 47.5; H, 7.0; N, 13.9%) vmax 3420, 3020, 2660, 2225
(n h +3), 1650, 1580, 1540 and 1405 - 1cm ; n.m.r • (D20^  6
6.90-5.80 (2H, multiplet) and 3.77 (2H, doublet J=5.5 Hz). 
The compound was shown to be homogenous by TLC in several 
solvent systems and gave a yellow colour with ninhydrin.
(B) BICUCULLINE AND ANALOGUES 
Bicucul1ine
The bicuculline (Fluka, AG) used in all investigations 
was identified on the basis of the following observations, 
m.p. 201-205° (lit. m.p. 199°; Edwards and Handa, 1961).
(Found: C, 65.4; H, 4.7; 3.8. Calc . for C2qH 17NO • C, 6 65 .
H, 4.7; N, 3.8%). v 2900, 1745max (C=0), 1650, 1620, 1505
1485, 1440, 1380 , 1365, 1315, 1260, 1245, 1210, 1120, 1070
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1 0 5 0 ,  1 0 2 5 ,  and  990 cm *; n . m . r  . (;CDCl ^ ) 6 6 , 9 3  and  6 . 8 4  
( 1H,  d o u b l e t  J = 8  H z ) ,  6 , 5  6 ( 1H,  s i n g l e t ) ,  6 . 8  4 (1H,  s i n g l e t ) ,
6 2  2 and  6 / 1 3  (2H,  d o u b l e t  J  = 8 H z ) ,  6 , 1 3  ( 2H,  s i n g l e t ) ,  5 , 9 1  
(2H,  s i n g l e t ) ,  5 , 5 5  a n d  5 , 0 0  (1H , d o u b l e t  J = 4  H z ) ,  4 , 0 5  and  
4 , 0 0  ( 1H,  d o u b l e t  J = 4  Hz)  a n d  3 , 0 0 - 2 . 0 0  ( 7H,  m u l t i p l e t ) ;  
ma s s  s p e c t r u m  no m o l e c u l a r  i o n ,  m/ e  190 ( M- C^Hr 0 ^ ) ,  The 
c o mp o u n d  was  f o u n d  t o  be  h o m o g e n o u s  by  TLC i n  t h r e e  s o l v e n t  
s y s t e m s :  n - b u t a n o l / a c e t i c  a c i d / w a t e r  ( 4 / 1 / 1 ) ,  c h l o r o f o r m /
m e t h a n o l  ( 1 / 1 )  and  c y c 1o h e x a n e / c h 1 o r o f o r m / 33% e t h a n o l i c  
d i me  t h y  1 a m i n e  ( 5 / 4 / 1 )  - s p o t s  l o c a t e d  w i t h  i o d i n e .
B i c u c u l l i n e  ( P i e r c e )  g a v e  i n f r a r e d  a n d  n . m . r .  s p e c t r a  
i d e n t i c a l  t o  t h a t  o f  t h e  a b o v e  s a m p l e ,  m . p .  2 0 3 - 2 0 7  
( F o u n d :  C,  6 5 . 8 ;  H,  4 , 7 ;  N,  3 . 8 % ) .  The  b e h a v i o u r  on TLC
was i d e n t i c a l  t o  t h a t  o f  t h e  a b o v e  s a m p l e ,
S a l s o l i n o l  h y d r o c h l o r i d e
The  p r o c e d u r e  e m p l o y e d  was  b a s i c a l l y  t h a t  o f  Wh a l e y  and  
G o v i n d a c h a r i  ( 1 9 5 1 ) ,  3 - ( 3 , 4 - D i h y d r o x y p h e n y 1 ) e t h y l a m i n e
h y d r o c h l o r i d e  ( 1 . 5 1  g)  a n d  a c e t a l d e h y d e  ( 0 . 7 9  g)  w e r e  
d i s s o l v e d  i n  200 ml  o f  w a t e r  by  s t i r r i n g ,  a n d  t h e  s o l u t i o n  
a l l o w e d  t o  s t a n d  a t  r oom t e m p e r a t u r e  f o r  3 d a y s .  The  
s o l u t i o n  was  e v a p o r a t e d  t o  d r y n e s s  i n  a v a c u u m t o  y i e l d  an 
o i l ,  w h i c h  c r y s t a l l i z e d  on s t a n d i n g  a s  a y e l l o w  s o l i d .  
R e c r y s t a l l i z a t i o n  f r o m  e t h a n o l / e t h e r  g a v e  v e r y  p a l e  y e l l o w  
c r y s t a l s ,  m . p .  2 1 7 - 2 2 2 °  ( F o u n d :  C,  5 5 . 3 ;  H,  6 . 7 ;  N,  6 . 3 .  
C a l c ,  f o r  Ci n H N 0 _ C 1:  C,  5 5 . 7 ;  H,  6 . 5 ;  N,  6 . 5 % ) .  v 
3 0 8 0 ,  1590  ( a r o m a t i c  C = C ) , 1 5 2 5 ,  885 a nd  865 cm *; n . m . r .  
( D O )  6 6 . 7 5  ( 2H, s i n g l e t ) ,  4 . 5 4  ( m u l t i p l e t ) ,  3 . 3 8  (2H,  
m u l t i p l e t ) ,  2 . 9 5  ( 2H,  m u l t i p l e t )  a nd  1 , 6 0  ( 3H,  d o u b l e t  
J = 7 H z ) .
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6,7-Dihydroxy-l,2,3,4-tetrahydroisoquinolLne hydrochloride
3 - (3,4-D lhydroxypheny1)e t.hy1amine hydrochloride (1.52 g) 
and formaldehyde solution (containing approximately 0.54 g 
of formaldehyde) were dissolved in 200 ml of water and 
allowed to stand at room temperature for 24 hours. This 
solution was evaporated to dryness in a vacuum, but 
recrystallization of the product (ethano1/ether, charcoal) 
was hindered by the precipitation of a green oil . The cloudy 
supernatant was decanted and further trituration with ether 
gave a crystalline solid. The procedure was repeated 
several times to yield a yellow crystalline compound, m.p. 
232-244° (lit. m.p. 262°; Buck, 1934) (Found: C, 54.1; H,
6.2; N, 6.7. Calc, for C H N02C1: C, 53.6; H, 6.0; N, 7.0%)
N.m.r. (D^O) 6 6.83 (2H, doublet J=3 Hz), 4.30 (2H, singlet), 
3.45 (2H, multiplet) and 2.97 (2H, multiplet). 
Aminophthalidylmethane hydrochloride
The procedure of Ullyot, et a 1 . , (1945) was used to
synthesise this compound. Phthaldehydic acid was condensed 
with nitromethane to give phthalidyInitromethane as 
colourless crystals, m.p, 128.5-132.5° (lit. m.p. 130-131°; 
Ullyot, et a 1 . , 1945). The nitro compound (4 g) was 
reduced to the desired product with 10% pa 11adium/carbon 
(1.1 g) and recrystallized from ethanol as colourless 
crystals, m.p. 245-250.5° (lit. m.p. 247-250°; Ullyot, et al.
! 9 45) . ^ Hi ax 3460 (N“H) > 3 000 and 1760 cm" 1 (C = 0); n.m.r.
(D20) 6 8.10 (4H, multiplet), 6.20 (1H, 2 doublets J=4 Hz) 
and 4.34-3.06 (2H, multiplet).
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(C) 4-AMINO-3-HYPROXYISOXAZOLE
Attempted dehydrogenation of cycloserine (1)
(1) To an aqueous alcoholic solution of cycloserine 
(300 mg), prepared by adding just sufficient water to effect 
solution, were added N-bromosuccinimide (593 mg) and 
dibenzoyl peroxide (81 mg), and the solution refluxed for
5 minutes. There was an almost immediate development of a 
yellow colouration, and the solution became colourless again 
after ca. 2 minutes. The resultant solution was filtered 
while hot and the solvent removed in a vacuum to yield pale 
yellow crystals. TLC (silica gel G) indicated this product 
contained two components. The fraction of low Rf was 
identified as unchanged cycloserine on the basis of its 
identical chromatographic behaviour to an authentic sample.
The fraction of high Rf was separated by preparative TLC 
(silica gel G, employing CHCl^/10% ethanol as the solvent) 
and elution, and subsequent isolation gave pale yellow crystals 
Recrystallization from ethanol gave colourless crystals (70 
mg, 21%), which were identified as succinimide by their m.p. 
126-128.5°, mixed m.p. 124-128° (lit. m.p. 126-127°; Pollock 
and Stevens, 1965c), and infrared spectrum.
(2) Cycloserine (400 mg) was dissolved in ca. 120 ml of
dimethylsulphoxide, active manganese dioxide (4.0 g) (prepared 
by the procedure of Pratt and McGovern, 1964) was added and 
the mixture stirred at room temperature for 35 hours. This 
resultant mixture was filtered several times to remove 
insoluble inorganic material and the dimethylsulphoxide 
removed in a vacuum (ca. 50°/2mm) to yield a brown product 
containing some colourless crystals. This crystalline compound 
was identified as dimethyl sulphone on the basis of melting
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point and n.m.r. spectrum - m,p. 110.5-112° (lit. m.p. 109 ; 
Pollock and Stevens, 1965b) and n.m.r. (D^-DMSO) 6 3.00 
(singlet). The crude product was taken up in water, washed 
several times with benzene to remove the dimethyl sulphone, 
and the aqueous fraction evaporated to dryness in a vacuum to 
yield a yellow, partially crystallized oil. When redissolved 
in water and examined by TLC on silica gel G, this product 
was found to be identical to cycloserine.
(3) An alkaline solution of potassium ferricyanide 
(3.00 g of potassium ferricyanide in ca. 50 ml of IN sodium 
hydroxide) was added to an aqueous solution of cycloserine 
(330 mg in ca. 10 ml of water), and the yellow solution heated 
on a water bath for 3 hours. The resultant solution was 
extracted with chloroform (3 X 30 ml), the chloroform extract 
dried over sodium sulphate, and the chloroform removed in a 
vacuum to yield no product. The pH of the solution was 
adjusted to 7, and the extraction procedure repeated, but 
again no product was obtained. The solution was concentrated, 
but selective crystallization could not be induced, and the 
solution was evaporated to dryness in a vacuum to give a pale 
green crystalline solid. This product was dissolved in the 
minimum volume of hot water, ethanol added and the solution 
cooled in ice. The precipitated pale green crystals 
(probably potassium and ferric salts) were filtered and washed 
with ethanol. This procedure was repeated several times and 
the mother liquor, when examined by TLC on silica gel G with 
CHCl^/10% ethanol as the solvent system, contained two 
components. The major one possessed a Rf identical to that 
of authentic cycloserine, but the minor component could not 
be isolated because of copious quantities of inorganic 
material formed from the potassium ferricyanide.
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(4) Cycloserine (407 mg) was dissolved in the minimum 
volume of glacial acetic acid (ca. 120 ml) and a solution of 
mercuric acetate ( 1 „ 2 48 g dissolved in the minimum volume of 
glacial acetic acid) added. The solution was stirred at room 
temperature for several hours, but no reaction, as indicated 
by the precipitation of mercurous acetate, was observed.
When the solution was refluxed for 1 hour it darkened in 
colour and became deep red. The solution was evaporated to 
dryness in a vacuum to yield a brown solid, which when 
examined by TLC showed unreacted starting material and two 
other components. Attempts to isolate these components, which 
were probably decomposition products of cycloserine, were 
prevented by the extreme colouration of the product.
N-Formyl glycine ethyl ester (formamido ethyl acetate) (4)
The procedure employed was based on that outlined by 
Heyns and Grutzmacher, 1961. Acetic anhydride (90 ml) was 
added to a solution of glycine ethyl ester hydrochloride (3) 
(2.77 g) in formic acid (45 ml). Sodium formate (1.57 g) 
was then added portionwise to this solution, and when the 
vigorous exothermic reaction had subsided, the solution was 
heated on a waterbath at ca. 80u for 3 hours - initially the 
reaction was very vigorous with the solution boiling violently. 
The white precipitate was removed by filtration and the 
filtrate concentrated in a vacuum. The residue and 
accompanying liquid were extracted with ether, which was dried 
over sodium sulphate, and removed in a vacuum to yield a pale 
yellow liquid. Distillation gave a colourless liquid (1.75 g, 
67%), b.p. 105-106°/! „5 mm (lit. b.p. 142-144°/12 mm, 156- 157°/ 
18 mm; Kocher gin, 1960) (Found: C, 46.4, 46.3; H, 6.3, 6.8;
Calc, for C5HgN0^: C, 45.8; H, 6.9; N, 10.7%).N, 10.7.
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v 3320 (N-H), 2960 (C-H), 1730 (ester C=0), 1665 (amideITlcl X
C = 0) , 1520 , 1 375, and 1200 cm'1; n.m.r. CCC143 6 9.05 (1H,
singlet), 8.15 (1H, singlet), 4.05 (4H, multiplet and 1.25 
(3H, quartet).
ß,g-Diethoxyalanine ethyl ester (6)
This intermediate was prepared by a combination of the
procedures of Brown, 1949, N-formyl glycine ethyl ester was
converted to sodium ethyl norpenaldate (5) in almost
quantitative yield - this sodium enolate gave the expected
red colour with aqueous ferric chloride. Suitable treatment
with ethanolic hydrogen chloride gave g,g-diethoxyalanme
ethyl ester, b.p. 92°/2.2 mm, 99-100°/4.4 mm (lit. b.p.
710/0.1 mm; Brown, 1949) (Found: C, 52.4; H, 9.4; N, 7.1.
Calc, for C nH NO .: C, 52.7; H, 9.3; N, 6.8%). vfllm 33809 19 4 7 max
(N-H), 2965 (C-H), 2890 (C-H) and 1730 cm'1 (C = 0) .
g,g-Diethoxyalanine hydroxamic acid (7)
Methanolic solutions of hydroxy lamine hydrochloride
(2.09 g in 20 ml of anhydrous methanol) and potassium hydroxide
(1.69 g in 25 ml of anhydrous methanol) were prepared, and the
alkaline solution was added to the hydroxy 1 amine hydrochloride
solution. The resultant solution was cooled in ice to 0°, and
filtered to remove potassium chloride. A methanolic solution
of g,g-diethoxyalanine ethyl ester (2.36 g in 30 ml of
anhydrous methanol) was cooled to -5° and then added
dropwise to this hydoxylamine solution. After stirring at
room temperature for 48 hours, the solvent was removed in a
vacuum to yield a yellow oily solid, which gave a positive
ferric chloride test. Recrysta 11 ization from methanol/ether
(charcoal) gave a very poor yield of colourless crystals, m„p„
111-115°. v 3430, 3290, 3200 (all N-H and 0-H), 2980 (C-H),niEx
2900 (C-H), 1640 (C=0), 1500, 1120 and 1065 cm 1; mass spectrum
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m/e no molecular ion, 147 (M-C^H^O, 2%), 132 (M-CONHOH, 4),
113 (5), 103 (100%, base peak), 88 (147-CONOH, 8), 87 (7),
86 (132-C?H OH, 12), 75 ( 10 3-C 2 H ;, 51), 73 (8), 58 
(86-C2H4, 26) and 47 (75-C H , 76). The product gave a 
positive test with aqueous ferric chloride» All attempts to 
improve this procedure or scale it up were unsuccessful» One 
run gave not the hydroxamic acid, but glycine ethyl ester 
hydrochloride»
2-Phenyl-4-ethoxymethyleneoxazol-5-one (9)
2-Pheny1-4-ethoxymethy 1eneoxazo 1 - 5 - one was prepared from 
hippuric acid (8), acetic anhydride and triethyl orthoformate 
by an "orthoformate" synthesis (Cornforth, 1949) as pale 
orange needles, m.p. 98-99.5° (lit. m„p. 97-98°; Cornforth,
19 49) .
2-Phenyl-4-ethylthiomethyleneoxazol-5-one (10)
Treatment of 2-pheny1-4-ethoxymethy leneoxazo 1 - 5 - one with 
ethane thiol in pyridine gave the required product, which was 
recrysta 11 ized from ethanol (or aqueous ethanol) as pale 
yellow needles, m.p. 112-116° (lit. m.p. 121-123°;
Cornforth, 1949) (Found: C, 61.5; H, 4.7; N, 5.9; S, 13,8. 
Calc, for c 12H11N02S: C, 61.8; H, 4.8; N, 6.0; S, 13.7%). 
q-Phenylacetamido-3-ethylthiomethyleneacrylic acid (11)
2-Pheny1-4-ethy 11hiomethy 1eneoxazo1-5- one (5.4 g) and 
potassium hydroxide (5.2 g) in 600 ml of water were 
refluxed for 5 hours, The solution was acidified with 
concentrated hydrochloric acid (ca„ 5M) and evaporated to 
dryness in a vacuum, The resultant product was taken up in 
hot chloroform (3 X 100 ml), the chloroform extract dried 
over sodium sulphate, and the solvent removed in a vacuum to 
yield an off-white solid Re crystallization (charcoal) from
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chloroform/petroleum ether (b.p. 60- 80;j) gave colourless
crystals (2.9 g, 50%), m.p. 162-166.5 (Found: C, 57,3; H,
5.6; N, 5 5; S, 12.5, Calc, for C .,H N03S : C, 57.4; H, 5.2;
N, 5.8; S, 12.8%). v 3300 (N-H), 1690 (acid C = 0) , 1650in ci x
(amide C = 0) and 1590 cm'1 (C = C) .
a-Pheny1acetamido-ß-ethy 1thiomethy1eneacry1ic acid methyl ester
a-Phenylacetamido-ß-ethylthiomethyleneacrylic acid
(1.89 g) was dissolved in the minimum volume of methanolic
ether and treated with an excess of ethereal diazomethane.
Evaporation to dryness in a vacuum yielded a colourless oil,
which formed colourless crystals on standing (yield
quantitative), m.p. 128.5-131,5° (Found: C, 58.9; H, 5.7;
N, 5.3; S, 12.0. Calc, for C H NO S: C, 58.9; H, 5.7;
N, 5.3; S, 12.1%). v 3300 (N-H), 1720 (ester C=0), 1650max
(amide C=0) and 1600 cm 1 (C=C); n.m.r, (CDCl^) 6 7.85 (6H,
multiplet), 3.85 (3H, singlet), 2.90 (2H, quartet J=8 Hz) and
1.37 (3H, triplet J=8 Hz); mass spectrum m/e 265 (M ), 260,
234, 233, 205, 204, 190, 189, 173, 172, 106, 105, 104, 103,
100, 78, 77, 76, 50, 45, 44, 32, 31, 29, 28 (100%, base peak).
Attempted preparation of a-phenylacetamido-ß-ethy 1thio- 
methyleneacry lohydroxamic acid (13)
None of the following procedures were found to be suitable 
for the synthesis of the hydroxamic acid. (1) Treatment of 
a-phenylacetamido-3-ethy 1thiomethyleneacrylie acid methyl ester 
with hydroxy 1 amine in methanol at room temperature overnight. 
(2) Heating a-phenylacetamido-ß-ethylthiomethy lene aery 1ic acid 
methyl ester with hydroxyl amine hydrochloride in anhydrous 
methanol overnight in a sealed tube at 100°. (3) Stirring
a-pheny1acetamido-B-ethy 1thiomethy lene aery 1 ic acid methyl 
ester with hydroxylamine under aqueous conditions for 2\ days
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at room temperature.. (4) Refluxing q-pheny lace t ami do - 3- 
e thy 11 hi ome thy 1 ene ac ry 11 c acid methyl ester with hydroxy lamme 
hydrochloride and pyridine for 1 hour, (5) Heating 
a-phenylacetamido-3-ethylthiomethyleneacrylic acid methyl 
ester with hydroxy 1 amine in anhydrous methanol overnight in a 
sealed tube at 100°, (6) Refluxing a-phenylacetamido-3-
ethy lthiomethyleneacrylic acid with oxalyl chloride in dry 
benzene for 1 hour, and then treating with a chloroform 
solution of hydroxy1 amine. (7) Preparation via the acid 
chloride could not be employed because thionyl chloride with 
a-pheny1acetamido-3-ethy11hiomethy 1eneaery 1ic acid gave the 
N-chloroacid chloride, (8) Cleavage of 2-phenyl-4- 
ethylthiomethyleneoxazol-5-one with methanolic hydroxy1amine 
gave only a-pheny1acetamido-3-ethy 11hiomethy 1eneacry11c acid 
me thy 1 ester.
q-Phenylacetamido-3-ethylthiomethyleneacrylic acid 
cyanomethylene ester (12)
The cyanomethy 1ene ester was prepared from the 
corresponding carboxylic acid by a procedure similar to that 
of Stewart (1970).
a-Pheny lacetamido-3-ethylthiomethyleneacrylie acid 
(540 mg) was dissolved in the minimum volume of dry 
dimethylformamide (DMF, ca, 15 ml) and redistilled 
triethylamine (221 mg) was added, Redistilled
chloroacetonitrile (205 mg) was added dropwise to this solution 
and the mixture allowed to stand at room remperature for 2-3 
days. Colourless needle-like crystals, which had begun to 
form after a few hours, were filtered off and 30 ml of water 
was added to the mother liquor. The resultant solution was 
extracted with chloroform (3 X 30 ml), the chloroform extract 
washed with saturated sodium bicarbonate solution (3 X 30 ml)
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and with water (3 X 30 ml), and dried over sodium sulphate. 
Removal of the chloroform in a vacuum gave a partially 
crystallized solid, which was taken up in the minimum volume 
of hot chloroform, and precipitated as colourless crystals 
by the addition of petroleum ether (b„p„ 60-80°). 
Recrystallization from chloroform/petroleum ether gave 
colourless crystals (370 mg, 58%), m„p„ 123-125 (Found:
C, 58.1; H, 4.9; N, 9.9; S, 11.1. Calc, for C 14H N ^ S :
C, 57.9; N, 4.9; N, 9.7; S, 11.0%). v , . 3270 (N-H), 1720
m  ci x
(ester C=0), 1650 (amide C=0) and 1590 cm 1 (C=C); n.m.r. 
(CDC13) 6 7.75 (6H, multiplet), 4.90 (2H, singlet), 2.97 
(2H, quartet J = 8 Hz) and 1.40 (3H, triplet J = 8 Hz); mass 
spectrum m/e 290 (M *, 1%), 234 (2), 233 (11), 229 (3), 106 
(6), 105 (70), 100 (3), 78 (3), 77 (25), 76 (3), 50 (3), 45
(2), 44 (3), 39 (2), 32 (6), 29 (6) and 28 (100%, base peak). 
4-Benzoylamino-3-hydro xyisoxazole (14)
a-Phenylacetamido-ß-ethy1thiomethylene aerylic acid 
cyanomethylene ester (246 mg) and hydroxy 1 amine hydrochloride 
(372 mg) were dissolved in the minimum volume of dry DMF 
(approximately 40 ml), and redistilled triethy1 amine (542 mg) 
added. The reaction mixture was allowed to stand at room 
temperature until it had become colourless - initially the 
reaction mixture was bright yellow in colour, with the 
evolution of pungent vapour (ethane thiol/triethylamine), but 
became colourless on standing (4-8 days, depending on the 
scale of the reaction). The precipitated triethylamine 
hydrochloride was filtered, washed with a small volume of 
dry DMF, and the combined mother liquors applied to the top 
of a Dowex 1 X 2 (50-100 mesh, OH" form) column (4cm X 25cm, 
or sufficient to adsorb all the DMF solution), washed to
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neutrality with water, eluted with approximately 2M aqueous
acetic acid and the fractions giving a positive test with
aqueous ferric chloride solutions collected (Frater-Schroder,
et a 1 . , 1969). The acetic acid eluant was evaporated to
dryness in a vacuum (approximately-50°/water pump pressure)
to yield a pale yellow oil, which crystallized on standing,
or on tritituration with acetone/ether, as colourless
crystals. Filtration, washing with ether and
recrysta11ization from ethano1/ether (or better ethanol/
petroleum ether, b.p. 60-80°) gave colourless crystals (92 mg,
53%), m.p. 153-159°. v 3320 (N-H), 3175, 3025, 2900,max
2845, 1690 (benzoyl amide C=0), 1645 (ring amide C=0), 1610,
1580 and 1540 cm"1 *; n.m.r. (D6-DMS0/CDC1 ) 6 9.09 (1H, 
multiplet), 8.50 (1H, singlet), 8.10 (2H, multiplet), 7.58 
(3H, multiplet) and 4.20 (1H, doublet J=5 Hz); mass spectrum 
m/e 204 (M+), 177 (M-HCN), 176, 175, 173, 162, 161 (M-HCNO), 
160, 105 (135-NO, base peak, 100%), 77 (105-CO), 72, 59, 57,
55 and 51 (77-0^) .
4-Amino-3-hydroxyisoxazole (2)
(1) 4-Benzoy1 amino-3-hydroxyisoxazo1e (415 mg) was 
dissolved in 6 ml of 70% sulphuric acid (4.2 g) by warming,
and the resultant solution refluxed for 10 minutes. The 
resultant pink solution was cooled in ice, and the 
precipitated crystals filtered and identified as benzoic acid 
by their m.p. and infrared spectrum. The filtrate was
chromatographed on a Dowex 50W (H ) X 8 (100-200 mesh) column,
first washing with water and then eluting zwitterionic 
products with 2% aqueous ammonia. The eluant was evaporated
to dryness in a vacuum, the residue dissolved in water and
again evaporated to remove last traces of ammonia, and the
9 2
crystalline product re crysta 11ized (charcoal) from water/ 
ethano1/ether as colourless crystals (30 mg, 20%) (Found:
C, 31.1; H, 7,3; N, 17.9. Calc, for glycine C H N02: C,
3 2 o0; H, 6 „ 7; H, T8.7|%). The product was found to be 
homogenous by TLC in two solvent systems (n-butanol/acetic 
acid/water, 4/1/1, located with iodine; sec-butanol/acetone/ 
dlcyc1ohexy1amine/water, 10/10/2/5, located with ninhydrin),
and possessed a Rf and an infrared spectrum identical to 
that of an authentic sample of glycine.
(2) The acid hydrolysis was carefully examined by TLC 
on cellulose of small scale reactions employing n-butanol/ 
acetic acid/water (4/1/1) as the solvent system and spraying 
the plates with ninhydrin. Conditions were investigated by 
varying the acid (sulphuric, hydrochloric and hydrobromic) 
and its concentration, the solvent '(acetic acid, dioxan and 
ethanol), the reaction time (0-50 minutes), and the reaction 
temperature. A glycine marker was always run concurrently 
and a spot of identical Rf had always appeared after 
approximately 10 minutes heating. A yellow spot of lower Rf 
than glycine was always formed first, but on longer heating a 
spot of identical Rf to glycine formed, followed by two spots 
of lower Rf than the initial product. The best conditions 
for hydrolysis appeared to be a 10 minute reflux with 10 
moles of 2M hydrochloric acid, diluted 1:1 with 2M aqueous 
acetic acid.
(3) 4-Benzoylamino-3-hydroxyisoxazole (200 mg) was 
refluxed with 4.9 ml of 2M hydrochloric acid and 4,9 ml of 
2M acetic acid for ten minutes. The solution was cooled in 
ice, evaporated to dryness in a vacuum, and the resultant 
colourless product dissolved in approximately 3 ml of water,
9 3
and subjected to preparative chromatography on cellulose.
The fraction of high Rf was eluted with hot ethanol 
(4 X 15 ml) and evaporated to dryness in a vacuum to yield a 
compound, which was recrysta1 1 ized-from ethanol/petroleum 
ether (b.p. 60-80 ) as colour less~ .crystals (80 mg, 40%) - 
m,p. and infrared identical with, the starting material„ The 
ninhydrin positive fractions were eluted with hot water 
(4 X 15 ml), the combined extracts filtered and evaporated to 
dryness in a vacuum to yield a colourless crystalline solid. 
When this product was examined by TLC two components were 
found - one with a Rf corresponding to glycine.
The reaction was repeated several times, and the 
ninhydrin positive products combihed and applied to the top 
of a paper column. Employing n-butano1/acetic acid/water 
(4/1/1) as the solvent system, the desired product could be 
clearly separated from glycine by this procedure (product 
Rf=0.27 and glycine Rf=0,34 by descending paper chromatography 
on paper identical to that of the column). The fractions 
containing this product were examined by TLC on cellulose to 
check their purity, combined and carefully evaporated to 
dryness in a vacuum at room temperature. When the resultant 
product was examined by TLC it always contained some glycine, 
and attempts to remove this glycine impurity by preparative 
TLC on cellulose were unsuccessful.
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3 . ENZYMIC STUDIES 
Brain GABA transaminase
Male rats (150-200 g) were decapitated, the brains 
rapidly excised, the cerebral hemispheres dissected and as 
much as possible of the underlying white matter removed.
The remaining cerebral grey matter (ca 450-550 mg/rat) was 
homogenised in 10 volumes of - ice-r cold 0.32 M sucrose 
(containg 0.5 mM dithiothreitol). The homogenate was 
centrifuged at 700 g for 10 minutes and the supernatant 
recentrifuged at 7,000 g for 10 minutes. The resulting crude 
mitochondrial pellet was resuspended in 10 volumes of 15 mM 
pyridoxal phosphate (containing 0.5 mM dithiothreito1) at pH 
7.9. This GABA transaminase preparation was stored frozen in 
dark glass vials wrapped in aluminium foil. Maximum activity 
was obtained by thawing and freezing several times, after 
which activity remained constant for at least 3 months.
The GABA transaminase activity in the preparation was 
assayed as follows. A stock substrate mixture containing
2 mM_ 2-oxoglutarate, 1 mM succinate, 10 mM dithiothreitol,
3 mM NAD and 0.3 mJ4 pyridoxal phosphate in 100 mM Tris buffer
at pH 8.5, was made up and stored in the deep freeze until
required. In the standard assay, 0.1 ml of this substrate
mixture was mixed with 0.05 ml of 6 mM GABA (containing 0.1 
14yC of GABA-1- C), 0.1 ml of an aqueous solution of the 
inhibitor, and 0.1 ml of 1 M pH 8.5 Tris buffer. This 
mixture was preincubated at 37° for 5 minutes, 0.1 ml of the 
enzyme preparation added, and incubation continued for 30 
minutes. The reaction was stopped by addition of 0.05 ml of 
25% aqueous trichloroacetic acid. The entire sample was then
"I"transferred to a column (1 X 4cm) of Dowex 50Wx4 (H ) resin,
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100-200 mesh, and the column eluted with water (4.5 ml), a
1 ml aliquot of the eluant taken and its radioactivity 
measured in 10 ml of Triton or dioxan scintillator. Assays 
were run at least in triplicate with appropriate zero time 
blanks and controls run concurrently.. The rate of GABA 
deamination measured in this way, which is similar to the 
method used by Hall and Kravitz (1967), was found to be linear 
with respect to both time and amoun..t_of enzyme preparation.
The GABA transaminase activity was completely inhibited by
0 02 mM amino-oxyacetic acid.
The inhibition of brain GABA transaminase activity by 
4-aminotetro1ic acid was investigated in detail with GABA as 
the variable substrate (0.133-0.667 mM, final concentration) 
and a-ketoglutarate at a fixed concentration.
The possibility that 4-aminotetro1ic acid was a substrate 
for this enzyme was investigated by replacing GABA in the 
incubation mixture by a ten fold concentration of 
4-aminotetro 1 i c aicd, and by scaling the reaction mixture up 
four times. Afer the usual preincubation, and incubation for 
30 and 60 minutes, the reaction was stopped by the addition 
of aqueous trichloroacetic acid. The incubation mixtures 
were cooled in ice, centrifuged to remove protein, the clear 
supernatant carefully removed and evaporated to dryness in a 
vacuum. The residues were taken up in an aliquot of water 
examined for glutamate by TLC on cellulose, employing 
n-butano1/acetic acid/water (4/1/1) as the solvent system. 
Although blanks contained some endogenous glutamate, there 
was no apparent formation of this amino acid with 
4-aminotetro1ic acid - with GABA as the amino donor there was 
an increasing production of glutamate with time.
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Quantitative amino acid analyses were also carried out using 
a modified Technicon Auto Analyser (James, 1972) to further 
investigate the possibility that 4-aminotetro1ic acid might 
be a substrate for the brain transaminase.
Bacterial GABA transaminase
An extract of Pseudomonas fluorescens (Sigma Chemical 
Co., Type III acetone powder) was employed in a coupled 
spectrophotometric assay (Scott and Jakoby, 1959) under 
conditions similar to those of'Lamar (1970). The final 
reaction mixture contained 1 mM 2-oxoglutarate, 0.5 mM NADP, 
0.1 mM pyridoxal phosphate, 50 mM pH 7.5 phosphate buffer, 
variable concentrations of GABA (1-10 mM) and inhibitor as 
required. Appropriate mixtures were made up immediately 
prior to the experiment and preincubated at 30° for 10 
minutes. Aliquots of 0.95 ml were transferred to 
spectrophotometer cells and the reaction initiated by 
addition of 0.05 ml of enzyme solution (10 mg of acetone 
powder/ml of 50 mM pH 6.8 phosphate buffer containing 1 mM 
dithiothreito1). The optical density was measured at 1 
minute intervals (generally from the second minute after 
addition of enzyme) at 340 my (Shimadzu QR50 
Spectrophotometer) over a 10 minute period at 30°. The 
reaction showed a slight lag phase and initial velocities 
were calculated from the linear phase determined graphically.
The inhibition by 4-aminotetro1ic acid of the initial 
velocity of the reaction catalysed by GABA transaminase was 
measured with GABA as the variable substrate (1-10 mM), at 
a fixed concentration of 2-oxoglutarate (1 mM) .
To determine whether 4-aminotetrolic acid was a 
substrate of this enzyme, GABA was replaced in the standard
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reaction mixture by 10 mM 4- ami notetro1ic acid, and, after 
preincub at ion at 37 for 10 minutes, the enzyme was added and 
the reaction mixture incubated at 37° for 1 hour. The 
mixture was then concentrated in a vacuum and examined for 
glutamate by thin layer chromatography on cellulose (Avicel) 
plates, employing n-butano 1 /aceti.c axid/water (4/1/1) as the 
solvent system. By this procedure concentrations of glutamate 
in the original reaction mixture as low as 0.05 mM could be 
detected after spraying the plate with ninhydrin.
The radiochemical assay developed for brain GABA 
transaminase was easily modified for the screening of 
inhibitors against the bacterial enzyme. An incubation time 
of 10 minutes was employed with 0.1 ml of enzyme solution 
(5 mg acetone powder/ml of 50 mM phosphate buffer pH 6.8, 
containing 1 mM dithiothre.itol) being added.
Brain L-glutamic acid decarboxylase
A freshly prepared extract of rat cerebral grey matter 
was used in a radioactive assay based on that described by 
Molinoff and Kravitz (1968). The grey matter was isolated 
as described above and homogenised in 10 volumes of cold 
25 mM pH 6.3 phosphate buffer containing 0.2 mM pyridoxal 
phosphate, 0.2 mM dithiothreitol, and 0,25% v/v Triton X-100. 
To 0.1 ml of this extract was added 0.1 ml of 25 mM pH 6.3 
phosphate buffer containing the inhibitor at the required 
concentration. After preincub ation at 37° for 5 minutes, the 
reaction was initiated by addition of 0.1 ml of 5 mM
3L-glutamate (containing 0.1 yC of H-L-glutamate), incubated 
at 37° for 30 minutes and the reaction mixture rapidly 
transferred to a column (0.7 X 5cm) of Dowex 1 X 8  (acetate) 
resin, 100-200 mesh. The radioactive GABA formed during the
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reaction was eluted with 4.7 ml of water and the 
radioactivity of an aliquot (1 ml) of the eluant measured 
using 10 ml of Triton or Dioxan scintillator. Appropriate 
zero time blanks and controls were run concurrently. No 
"GAD II" activity (Haber, et a1., 1970) was found in the
preparation, the decarboxylase activity of which was 
completely inhibited by 1 mM amino-oxyacetic acid. The rate 
of decarboxylation was linear with respect to time for at 
least 1 hour.
Bacterial L-glutamic acid decarboxylase
The assay procedure was similar to that used for brain 
glutamate decarboxylase, with an incubation mixture 
prepared from 0.1 ml of enzyme solution (1 mg of E . co 1 i 
acetone powder, Worthington Biochemical Corp., per ml of 
100 mM pH 5.0 sodium acetate buffer) and 0.1 ml of 100 mM 
pH 5.0 sodium acetate buffer containing the inhibitor at 
the required concentration. After prein cubation at 37° for 
5 minutes, 0.1 ml of 0.5 mM L-glutamate (containing 0.1 yC
3of H-L-g1utamate) was added and incubation continued for 
10 minutes. The enzyme activity measured in this manner was 
completely inhibited by 1 mM amino-oxyacetic acid and the
rate of reaction was linear for 10 minutes.
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4. UPTAKE STUDIES
GABA uptake by rat brain "maxi" slices
The method of Blasberg and Lajtha (1966) was adapted 
for these uptake studies. Young adult Wistar rats 
(150-200 g) were decapitated, their brains rapidly excised, 
the cerebral hemispheres dissected and the underlying 
white matter carefully removed. Brain slices (first and 
second slices, approximate thickness .35-.45 mm) were cut by 
hand with a Gillette blade from both hemispheres, placed in 
4 mis of oxygenated standard medium at 0° (bubbled with 95% 
oxygen/5% carbon dioxide for 1 minute) and preincubated in a 
shaking water bath at 37c (shaking rate 120 strokes/minute, 
amplitude of stroke 3cm) for 30 minutes to equilibrate with 
the medium. The standard medium contained 10 mM glucose,
128 mM sodium chloride, 5 mM potassium chloride, 2.7 mM 
calcium chloride, 1.2 mM magnesium sulphate, 5 mM sodium 
dihydrogenphosphate and 50 mM tris adjusted to pH 7.4 with 
hydrochloric acid, and inhibitor at the required concentration 
in the appropriate incubation bottles. After preincub ation 
0.1 ml of 4.1 mM GABA (containing 0.05 yC of GABA-1-^^C) was 
added and the slices incubated for 60 minutes at 37°. The 
slices were removed with a wire rider, drained on a filter 
paper to remove excess medium, weighed, transferred to a 
centrifuge tube containing 2 mis of 3% perchloric acid, 
allowed to stand for 30 minutes, homogenised by shaking on a 
vortex contact shaker and centrifuged in a M.S.E. bench 
centrifuge. An 0.5 ml aliquot was removed, added to 10 ml 
of dioxan scintillator and the radioactivity determined by 
counting. The determination of medium counts allowed the 
specific activity and hence the concentration of GABA
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accumulated to be calculated. It was assumed that there was 
insignificant metabolism of GABA during the 60 minute 
incubation period and hence the radioactivity was a direct 
measure of the GABA accumulated by the brain slices.
GABA uptake by rat brain "mini" slices 
(a) Preliminary screening
The procedure used was basically that of Iversen and
Neal (1968). Rat cerebral grey matter was cut at 0.1 mm
intervals with a Mcllwain tissue chopper in two directions
at 45°, and the resulting prism-shaped slices suspended in
5 volumes of ice-cold oxygenated incubation medium
(Krebs-Ringer phosphate containing 118.5 mM sodium chloride,
4.75 mM potassium chloride, 1.77 mM calcium chloride, 16.2 mM
sodium phosphate buffer pH 7.4 and 5.55 mM glucose). Slices
(batches of 10 mg, dispensed by the use of an Eppendorf 50
yl automatic pipette), were preincubated at 25° with
- 4inhibitors (5 X 10 M) in 10 mis of freshly oxygenated medium,
3H-GABA (0.25 yC) added to give a final concentration of 
-  81.25 X 10 M, and incubation continued for 10 minutes. The 
slices were collected by rapid filtration through Whatman 
No. 1 filter paper (23mm diameter circles), the paper washed 
with cold medium (10 ml) and transferred to scintillation 
vials. The radioactivity was extracted from the slices by 
soaking in water (1 ml) for 1 hour, and measured after 
addition of scintillator (10 ml). CPMs were converted to 
DPMs via external standards, blanks substracted, and mean 
values (± S.E.M.) of results from quadruplicate experiments 
were calculated and compared with control values using a 
PDP8I computer. The uptake of radioactivity determined in
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this way over 10 minutes was used as an approximate measure 
of the initial velocity of GABA uptake (Iversen and Neal, 1968)0
(b) Comparison of potencies of- inhibitors - 
ICqn determination
The most active inhibitors revealed by the preliminary 
screening were tested as above (inhibitors preincubated with 
slices for 15 minutes and incubated for 10 minutes) over a 
range of inhibitor concentrations at a constant GABA 
concentration. IC,_q va^ues were determined by "probit 
analysis" of results as previously described (Iversen and 
J ohns ton, 19 71).
(c) Kinetic studies
The nature of the inhibition of the more powerful
inhibitors was investigated by kinetic studies in which the 
3rate of H-GABA uptake was measured in the presence and 
absence of fixed concentrations (two concentrations were 
always employed) of the inhibitor (preincubated with the 
tissue for 15 minutes and incubated for 10 minutes)„ The 
initial velocity data obtained were analysed by the methods 
of C1 e 1 and (1963a,b) and the mode of action of the inhibitors 
and the inhibition constants evaluated in the light of 
structural considerations.
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5.. ANALYSIS OF KINETIC DATA
Initial velocity data from inhibition studies of the 
transaminases and GABA uptake were analysed by the methods 
of Cleland (1963a,b) using his Fortran programmes on an 
IBM360/50 computer. The preliminary fit of data was to 
equation (3), and was weighted to the fourth power of the 
velocity, assuming equal variance for the velocities 
(Wilkinson, 1961).
Slopes (K/V) and intercepts (1/V) from computer fits 
were plotted against inhibitor concentration, and on the 
basis of these replots the initial velocity data were 
fitted to equation (4) for linear non-competitive 
inhibition, to equation (5) for linear competitive 
inhibition, and to equation (6) for parabolic competitive 
inhibition.
v = VA (3)
K + A
v = VA (4)
K (1 + Y  ) + A(1 + t  )
is i i
v = VA (5)
K(1 + I ) + A
is
v = VA (6)
K U  ♦ i
i 1
+ 0 + A
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In the inhibition studies of the transaminases, the 
programmes used to analyse the date were weighted towards 
the most accurate determinations. However, in the uptake 
studies, while the concentration of GABA varied, the amount 
of radioactivity added to each incubation vial was constant, 
and hence the accuracy of each experimental point was 
essentially the same, and the weighting factors were deleted 
from the programmes.
Where appropriate weighted averages of the values for 
the inhibition constants from the computer analysis of 
experiments were calculated by equations (7) and (8) 
(Morrison and James, 1965).
Weighted mean of x values =
Z w . x .l l (7)
Z w i
and S.E.M. of weighted mean value = 1 (8)
/Z w i
where w = 1
[S.E.M. (X .)]1 2
V APPENDIX
104
APPEND!X
LACK OF EFFECT OF BICUCULLINE ON GABA 
INTO RAT BRAIN SLICES
UPTAKE
Slice w t (mg) CPM/mg mean ± S .E .M „
CONTROL 53 33 „ 5
4 7 41 „5
39 4 3.9 50.2±4.3 CPM/mg,
36 54.2 2.45+0.21 pmo1e
36 49.1 GABA/g wet
44 4 7.3 tissue (8 s lices)
24 59 .2
1 8 73.0
INHIBITOR 29 52.4
2 8 54.2
45 38.0 49.3+2.5 CPM/mg,
40 45.2 2.4010.12 umole
41 41.9 GABA/g wet
36 52.7 tissue (8 slices)
30 49.6
39 60.1
Rat brain cerebral cortical "maxi" slices were preincubated
with or without 0 „1 mM bicuculline for 30 minutes at 37°,
and incubated for 60 minutes at 37° against 0.1 mM 
14GABA- 1- C .
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